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Abstract 
 Parkinson’s disease (PD) is a chronic and progressive neurological disorder that 
causes both motor symptoms and non-motor symptoms in individuals. Overall, PD 
impacts the physical, emotional and social functioning in the lives of those impacted by 
the disorder. In 2001, Freed et al. investigated the effects of fetal tissue transplantation in 
participants with PD by conducting a double-blind sham-controlled surgery trial. The 
quality of life (QoL) study was conducted concurrently by McRae et al. (2004) in order to 
determine whether QoL improved in participants in the transplant group compared to the 
sham group after the one-year period of the double-blind.  
 Research regarding the long-term impact of the fetal tissue transplantation on 
individuals with PD is extremely limited and there is little known regarding the long-term 
impact of participating in a double-blind sham-controlled surgery trial. This study 
examined the longitudinal changes, from both a quantitative and qualitative perspective, 
in QoL after undergoing the fetal tissue transplantation surgery approximately 13-15 
years ago. There were a total of five participants who participated in the parent study 
(Freed et al., 2001) and original QoL study (McRae, 2004). All five participants 
completed an interview to gather qualitative information regarding their personal 
experiences over the last 13-15 years and four participants completed a questionnaire that 
measured several dimensions of QoL as well as optimism. The information gathered in 
the current study was plotted along with the data collected at baseline, 12, and 24 months 




QoL was thus charted for each of the four individuals as well as average scores at each 
time point on each measure. Interviews were transcribed and coded for themes in order to 
describe the experiences of the participants in the unique study.  
 In the current study, the changes on several aspects of QoL were examined over 
the last 13-15 years. The majority of the participants showed decline on all the measures 
assessing Physical functioning, Emotional functioning, and Social functioning as well as 
Optimism between the 10-12-year follow-up in 2008 and the current assessment. 
However, the decline in functioning on several measures was less than expected given the 
progression of their illness. The qualitative data (e.g., narratives) provided insight into 
possible explanations for the resiliency amongst the participants who participated in the 
transplant surgery trial including the participants’ dedication to contributing to our 
knowledge of PD and treatments of PD, strong social support, and internal drive to 
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Description of Parkinson’s Disease 
 Parkinson’s disease (PD) is a chronic neurologic disease that impacts the central 
nervous system.  James Parkinson, a British physician, described a complex set of 
symptoms in 1817 that later became known as Parkinson’s disease.  PD is characterized 
by motor symptoms including bradykinesia, resting tremor, stiffness, postural instability, 
and a broad spectrum of non-motor features including sleep problems, autonomous 
nervous system dysfunction, depression and dementia (Burch & Sheerin, 2005; Pfeiffer, 
2007; Rod, Hansen, Schernhammer & Ritz, 2010).  
 PD is the result of a loss of dopaminergic neurons in the substantia nigra pars 
compacta, which causes reduced dopamine release in the striatum (Clark, Reddy, Zheng, 
Betensky & Simon, 2011).  There are multiple genetic and environmental factors 
involved in PD (Simunovic et al., 2009).  Currently, there are two forms of PD 
recognized: a ‘familial’ or early-onset PD and an ‘idiopathic’ or late-onset PD that does 
not appear to exhibit heritability (Simunovic et al., 2009).  The ‘familial’ or early-onset 
PD is found in approximately less than10% of all PD patients and ‘idiopathic’ or late-
onset PD is found in approximately more than 85% of all PD patients.  Overall, the 
pathology of Parkinson's disease is a consequence of a combination of unknown genetic 




events (Maguire-Zeiss & Federoff, 2003; Miller & Federoff, 2005; Simunovic et al., 
2009). 
PD is currently diagnosed based on clinical criteria, and at this time, there is no 
definitive test for PD.  Diagnosis is generally based on the presence or absence of 
cardinal motor features associated with PD (e.g., tremors, rigidity, bradykinesia) and 
response to Levodopa (Rao et al., 2003).  The diagnosis of PD can often be challenging, 
particularly in the early stages of the disease when there is overlap between the 
symptoms in different syndromes (Jankovic, 2008; Tolosa, Wenning & Poewe, 2006).  
Persons with PD can sometimes be misdiagnosed for several years before the symptoms 
become obvious enough for a clear diagnosis. 
 The treatments for PD include drug therapies and surgical interventions targeted 
at reducing the symptoms associated with PD.  The surgical procedures are implemented 
when drug treatments are no longer effective in the later stages of the disease.  Current 
surgical treatments for patients with PD include thalamotomy, pallidotomy, and deep 
brain stimulation. Gene therapy, stem cell transplantation, and fetal tissue transplantation 
are additional surgical interventions for patients with PD that are in various stages of 
development and refinement. 
Onset and Prevalence 
 Today, PD is the most prevalent neurodegenerative movement disorder in adults 
(Borland et al., 2008).  PD affects up to one million people in the United States (National 
Parkinson Foundation, 2010).  More specifically, the disease affects approximately 2-3% 
of individuals over the age of 65 years (Cantuti-Castelvetri et al., 2007).  However, in 5-




40.  Overall, age-adjusted prevalence is 1% worldwide, and 1.6% in Europe, rising from 
0.6% at age 60-64 to 3.5% at age 85-89 (Clark & Moore, 2007; De Rijk et al., 1997; 
Zhang & Roman, 1993).  
 While the progression and symptoms of PD vary significantly among patients, 
research has found that bradykinesia, rigidity, and activities of daily living deteriorate 
faster in the earlier stages of the disease (Maetzler, Liepelt, & Berg, 2009).  Furthermore, 
cognitive impairments, speech difficulties, sleep problems and gait difficulties develop 
throughout the progression of the disease (Maetzler et al., 2009).  In the later stages of 
the disease, orthostatic dysfunction, visual hallucinations, and variability in heart rate 
develop (Maetzler et al., 2009).  The life expectancy of patients with PD has been shown 
to be lower than the general population (Hobson, Meara, & Ishihara-Paul, 2010).  In 
patients who do not develop dementia, the survival is shown to be similar to the general 
population (Hobson et al., 2010).  In other words, patients with dementia and with a 
younger onset of PD appear to have shorter life expectancies than other patients with PD 
(Hobson et al., 2010).  
Gender and Ethnicity 
 Evidence suggests the prevalence of Parkinson’s disease is higher in the male 
population (Cantuti-Castelvetri et al., 2007) with a 60% and 40% male to female ratio.  
There is limited evidence regarding the prevalence of PD in ethnic minority groups.  
However, current research found PD impacts diverse racial and ethnic groups worldwide 
and one-fifth of patients with PD in the United States are from ethnic minority groups 
(Schneider, et al., 2009).  However, more research needs to be conducted regarding the 





 There are several cardinal symptoms associated with PD.  The most common and 
recognizable feature of PD is a unilateral rest tremor (Shahed & Jankovic, 2007).  
Cardinal symptoms of PD include rigidity, akinesia or bradykinesia, postural instability, 
flexed posture, and freezing (Jankovic, 2008).  In addition, there are several secondary 
motor symptoms that are present in patients with PD including the re-emergence of 
primitive reflexes and unintended movements accompanying voluntary activity in 
homologous muscles (Jankovic, 2008; Thomas, 1994; Li et al., 2007; Wu, Sitburana & 
Jankovic, 2007).  Neuro-opthalmological abnormalities such as decreased blink rate, 
ocular surface irritation, altered tear film, visual hallucinations, blepharospasm and 
decreased convergence also occur in individuals with PD (Biousse et al., 2004; Jankovic, 
2008).  Individuals with PD experience respiratory disturbances, which can be either 
restrictive or obstructive (Jankovic, 2008).  Non-motor symptoms are present in 
individuals with PD.  These include autonomic dysfunction, cognitive and 
neurobehavioral abnormalities such as dementia sleep disorders, and sensory 
abnormalities (Jankovic, 2008).  Sensory symptoms include olfactory dysfunction, pain, 
paresthesia, akathisia, oral pain, and genital pain (Jankovic, 2008).    
Drug Treatment 
 Pharmacological treatments for PD are tailored to the specific needs and 
circumstances of the patient with PD (Schapira, 2005).  As a result, treatments can vary 
significantly in patients depending on their stage of the disease and response to 




patients with PD when symptoms interfere with daily activities such as work and social 
activities (Schapira, 2005).   
 Currently, pharmacologic treatments primarily focus on improvement of the 
motor features associated with PD.  Other pharmacologic treatments are used to treat 
non-motor symptoms such as depression, anxiety, hallucinations, sleep disorders, sexual 
dysfunction, bowel problems and gait, pain, and fatigue given these symptoms can cause 
significant distress to patients with PD.  There have been several pharmacological 
treatments shown to be effective in treating the non-dopaminergic symptoms of PD.  
Surgical treatment 
  Surgical treatments for PD have been taking place for over 100 years (Bronte-
Stewart, 2003).  New surgical approaches were developed in the early 1990s as a result 
of gaining a better understanding of the pathophysiology of PD (Walter & Vitek, 2004). 
For instance, there have been significant advances in understanding the basal ganglia 
physiology (Bronte-Stewart, 2003).  Thalamotomy was an early surgical procedure used 
to treat the resting tremor associated with PD. Unfortunately, there were multiple side 
effects associated with the procedure including an exacerbation of speech and gait 
disorders (Walter & Vitek, 2004).  Thalamotomy was not recommended following the 
introduction of the pallidotomy procedure and deep brain stimulation (DBS; Walter & 
Vitek, 2004).  One approach to DBS is the stimulation of the thalamus or the ventral 
intermediate nucleus, which has been shown to be effective in reducing the tremor in 
patients with PD (Walter & Vitek, 2004).  Another DBS procedure that has been 
implemented in patients with PD is the stimulation of the internal globus pallidus and 




symptoms associated with PD including akinesia and bradykinesia, rigidity, tremor and 
gait (Walter & Vitek, 2004).  
 Several other surgical procedures (i.e., neural transplantation) have been 
implemented in treating patients with PD.  There are two types of neural transplantation: 
stem cell surgery and fetal tissue surgery.  While there have been several surgical 
procedures used in treating PD, this study focused on neural transplantation, and more 
specifically, fetal tissue transplantation in persons with PD.  Fetal tissue transplantation 
surgery is the stereotactic implantation of human embryonic dopamine neurons into the 
brain (McRae et al., 2004).  In 2001, results of a double-blind, sham-surgery-controlled 
trial of the implantation of embryonic dopamine neurons in patients with severe PD were 
reported (Freed et al., 2001).  The goals of the study included determining if the 
implanted neurons survived in patients and if the implanted neurons led to a reduction in 
symptoms and signs associated with PD.  In addition, the study examined the effect of 
age on the efficacy of the transplantation of embryonic dopamine neurons.  The primary 
aim of the study was to determine whether the transplant group improved more than the 
participants in the sham group during the double-blind sham-controlled trial (Freed et 
al., 2001).  
The study found human embryonic dopamine neurons survived in patients with 
severe PD and that younger patients received some clinical benefits (Freed et al., 2001). 
Along with the neurological investigation of the fetal transplantation surgery trial, there 
was a concurrent examination of the quality of life among the participants in the double-





Quality of Life Study 
The quality of life (QoL) study was conducted by McRae et al. (2004) in order to 
determine whether QoL improved in participants in the transplant group compared to the 
sham group following the double-blind, sham surgery-controlled trial.  The study was 
conducted during the first year of double-blind follow-up and the participants were 
assessed at baseline, 4, 8, and 12 months after surgery.  The participants’ quality of life 
(QoL) was assessed by examining three different domains: physical, emotional and 
social functioning.  The physical functioning items assessed the patients’ perspectives of 
ADL’s, severity of symptoms, and how “free” or “restricted” participants felt “in doing 
what you want to do.”  The emotional functioning set of items assessed depressive 
symptoms, current and situational aspects of anxiety, stress, and degree to which the 
chronic illness interferes with usual life activities.  The social functioning set of items 
assessed aspects of both perceived social support as well as the amount of social 
interaction or activity experienced by each participant.  
The researchers found very few differences between the transplant and sham 
groups at any of the follow-up assessments.  Likewise, there were few changes over 
time. However, there were a number of significant differences between groups as well as 
changes over time based on perceived treatment or type of treatment participants’ 
thought they received (McRae et al., 2004).  Results indicated that those who thought 
they received the transplant reported improvements and those who thought they received 
the sham surgery reported a worsening of symptoms and outcomes regardless of actual 
type surgery they received.  As a result, the researchers found the placebo effect greatly 




Longitudinal Perspective  
As a follow-up to the original QoL study, an investigation of the longitudinal 
effects of the transplant among those who participated in the unique double-blind 
surgery trial was conducted by Cole (2009).  This study solicited information from the 
original participants approximately 10-12 years following the transplantation surgery.  
The individuals were located and agreed to participate.  They completed some of the 
original QoL measures as well as the NEO-FFI, a personality inventory (Cole).  There 
were several significant changes found from baseline to 10-12 years following the 
procedure regarding the physical functioning, emotional functioning and social 
functioning of QoL (Cole).  In addition, significant changes since baseline were found 
on the Neuroticism, Extraversion, Openness to experiences, and Conscientiousness 
factors of the NEO-FFI (Cole).  The study conducted by Cole examined the quantitative 
data to explore the impact of this surgical trial on participants over an extended period of 
time.  However, there has never been an examination of the qualitative aspects of the 
participants’ experiences in this study.  
Mixed Methods 
 A mixed methods approach is the integration of multiple forms of data including 
both quantitative and qualitative data.  More specifically, a mixed method design 
incorporates real-life understandings, multi-level perspectives and cultural influences 
along with a collection of quantitative data (Creswell, Klassen, Plano Clark & Smith, 
2011).  There are many strengths in exploring qualitative data, including the ability to 
examine different contexts, the meaning of human lives and previously unknown 




approach and to integrate the quantitative and qualitative data to use the strengths of 
both approaches in examining the longitudinal perspectives of participating in a double-
blind, sham-controlled surgery trial.  However, during the data analysis phase of the 
study, it became evident that the quantitative data could not be analyzed statistically due 
to the small sample size and as a result, a qualitative approach was used as opposed to a 
mixed methods approach.  	  
Statement of the Problem 
The research on fetal transplantation in patients with PD is limited.  Furthermore, 
there is limited research pertaining to long-term effects of participating in a double-
blind-sham-controlled study.  While there has been one long-term follow-up 
investigation, there has been no qualitative data gathered on the impact of participating 
in the fetal transplant surgery trial.  This study examined the longitudinal impact on QoL 
of participating in the fetal transplantation study conducted by Freed et al. (2001) from 
both a qualitative and quantitative perspective.  To examine the impact of participating 
in the study and the course of the disease, the participants’ QoL including Physical 
functioning, Emotional functioning, and Social functioning was assessed along with 
Optimism.  This qualitative and quantitative investigation provided information that is 
possibly valuable to neurologists and scientists interested in developing effective 
treatments for PD.  The quantitative data explored the current status of the participants 
approximately 13-15 years following the fetal transplantation.  The qualitative data 
provided a glimpse into the personal experiences of the participants and provided a 
broader understanding of the impact of participating in this unique double-blind study 




The participants in this study were the surviving participants of the study 
conducted by McRae et al. (2004).  In the study conducted by Freed et al. (2001), there 
were a total of 40 participants admitted to the Irving Center for Clinical Research at 
Columbia University for a total of five assessments: two before surgery at baseline, and 
at 4, 8 and 12 months following the surgery.  To examine the effectiveness of the fetal 
tissue transplantation surgery, 20 participants were assigned to the transplant surgery and 
20 participants were assigned to receive the sham surgery.  The participants assigned to 
the sham surgery were given the option to undergo the procedure following revealing of 
the double-blind.  All of the patients and medical staff who were attending the patients 
were blind to the treatment-group assignments throughout the study.  The study was 
conducted to examine the effectiveness of the fetal tissue transplantation surgery and, 
more specifically, to determine if the participants in the treatment group demonstrated 
greater improvements than the participants who received the sham surgery. 
 The QoL study by McRae et al. (2004) was conducted to assess the QoL in the 
participants.  The researchers assessed the participants’ QoL at baseline, 4, 8 and 12 
months following surgery (McRae et al., 2004).  A total of 30 out of the 40 participants 
in the study by Freed et al. (2001) agreed to participate in the study and in this group 
there were 12 participants who received the transplant and 18 participants who received 
the sham surgery (McRae et al., 2004).  The purpose of the study was to determine if 
QoL improved more in the treatment group than in the sham surgery group (McRae et 
al., 2004).  Furthermore, the researchers investigated whether participants who thought 
they received the transplant improved more than the participants who thought they 




The present study used the quantitative data on QoL gathered in the original 
study at baseline, 12 and 24 months after the transplantation and follow-up data gathered 
in 2008.  The present study involved collecting quantitative and qualitative data 
regarding QoL and optimism from the surviving patients who participated in the original 
QoL study by McRae et al. (2004).  The study assessed longitudinal changes in QoL and 
optimism that have taken place over time from both a quantitative and qualitative 
perspective.  
Research Questions 
1. What is the trajectory of change in QoL for all the participants in the current 
study from the baseline, 12 and 24 months after transplant, 10-12 follow-up 
assessment conducted in 2008 and current 13-15 year follow-up assessment?  
Because of the small sample size, no statistical analyses were performed. Instead, 
the averages for the participants on each measure were calculated and then 
plotted to examine the changes over time. In addition, individual scores on each 
of the measures were plotted over time. Thus, a mixed methods approach could 
not be used in the current study and as a result, a qualitative approach was used.  
2. What are the individual experiences of the participants who participated in the 
double-blind sham controlled transplantation study and original QoL study?  
3. Would the participants, who participated in original transplantation study, 







Limitations of the Study 
 There were several limitations present in the current study.  The first limitation 
was the small sample size in the current study.  The participants include only a small 
portion of the participants from the original QoL study (n=30) since several participants 
from the original QoL study have died and others have perhaps moved to a different 
location or were not able to be found.  As a result, their contact information was no 
longer valid.  
The second limitation was that the data were not generalizable to all patients with 
PD.  There were strict inclusion and exclusion criteria used in the original transplant 
study and, therefore, the current sample does not include patients with PD who may have 
other neurological disorders, chronic illnesses, or severe mental health issues.  
Additionally, the participants in the current study underwent an experimental surgery, 
12-month double blind condition and sham-controlled procedure, and as a result, their 
experiences are unique compared to other patients with PD.  The participants of the 
original transplant study (Freed et al., 2001) and original QoL study (McRae et al., 2004) 
volunteered to undergo a experimental surgical trial, which may set them apart from 
other patients with PD who may have declined to participate in a surgery trial.  Their 
experiences are extremely valuable in understanding the impact the original transplant 









 Chapter One presented an overview of PD, which included the physiology, onset, 
symptoms, drug and surgical treatments.  A detailed discussion of QoL and mixed 
method research design was also presented.  Chapter Two provides a detailed review of 




























 Chapter Two provides a broad overview of PD along with a discussion of 
pharmacological treatments, surgical interventions with an emphasis on fetal 
transplantation, long-term progression of PD, QoL and mixed methods research.  
 The literature reviewed in this chapter was retrieved using multiple databases.  
The database MEDLINE was used to provide information on history of PD, onset and 
prevalence of PD, symptoms of PD, drug treatments, and surgical interventions 
including the fetal transplantation surgery.  A secondary search was conducted using 
multiple databases including PsycINFO, and PsycARTICLES.  Topics in the second 
search were QoL, mixed methods research and treatment of PD.  
Definition of PD 
 James Parkinson, who wrote the Essay of the Shaking Palsy in 1817, was the first 
person to formally discuss the signs of this unusual disorder.  Jean Martin Charcot 
expanded the early description of PD by separating PD from multiple sclerosis and other 
disorders characterized by tremors (Goetz, 2011).  Moreover, Charcot recognized the 
work of James Parkinson and termed the disorder “Parkinson’s disease” instead of 
paralysis agitans (Goetz, 2011).  Today, PD is recognized as a progressive neurological 




include tremor, rigidity, akinesia or bradykinesia, postural instability, fixed posture and 
freezing (Jankovic 2008).  Non-motor symptoms include autonomic dysfunction 
(orthostatic hypotension, sweating dysfunction, sphincter dysfunction, erectile 
dysfunction), cognitive and neurobehavioral abnormalities (dementia, affective 
disorders, obsessive-compulsive and impulsive behavior), sleep disorders and sensory 
abnormalities (Jankovic, 2008). 
The etiology of idiopathic PD is still unknown despite PD being the most 
common neurodegenerative disorder in elderly populations and representing a 
considerable personal and societal burden on individuals with PD and their families 
(Rod, Hansen, Schernhammer, & Ritz, 2011).  Currently, there is no one technique or 
assessment that provides a primary diagnosis of PD.  Diagnosis of PD is based on a 
detailed record of a patient’s medical history along with a combination of physical and 
neurological assessments (Hughes, Daniel, Ben-Shlomo, & Lees, 2002). 
Despite the numerous treatment options available to individuals with PD, 40 % 
of individuals with PD continue to have motor fluctuations and 28% experience 
Levodopa-induced dyskinesias (Shrag & Quinn, 2000).  Currently, PD can not be cured; 
however, the symptoms of PD can be managed by medications for a number of years. 
Symptoms 
 The three cardinal symptoms of PD are bradykinesia, muscular rigidity and 
tremor (Pellicano et al., 2007).  Bradykinesia, or slowness of movement, primarily 
contributes to the disability associated with PD progression (Pellicano et al., 2007).  
Initially, bradykinesia will manifest itself as slow reaction time or planning, initiating, 




2008).  Muscular rigidity is an increase in resistance among the joints in forming passive 
movements.  Among individuals with PD, muscular rigidity only minimally contributes 
to disability.  Tremor is the most commonly associated symptom with PD.  Tremors are 
the uncontrollable shaking of an upper or lower extremity.  Tremors, in persons with 
Parkinson’s disease, can be a rhythmic, involuntary, or an oscillating movement of a 
body part.  Tremors have been shown to worsen as persons with PD focus on the tremor 
or become increasingly anxious (Dakof & Mendelsohn, 1986).  Rigidity is another 
symptom commonly associated with Parkinson’s disease and the presentation of rigidity 
often manifests itself as muscle stiffness, cramping or soreness.  In persons with PD, 
slowness of movement may also result as the motor program retrieval system becomes 
impaired, resulting in slowed movements (Marsden, 1989).  
 In addition to primary symptoms associated with PD, there are multiple 
secondary symptoms including constipation, decreased sexual libido, insomnia, hot 
flashes or chills, seborrhea, excessive sweating, conjunctivitis and impairment of visual 
spatial behaviors (Duvoisin, 1984; Mayeux, 1984).  The severity of motor symptoms, 
including both primary and secondary symptoms, and nonmotor symptoms can fluctuate 
and vary in individuals.  However, all three of the primary symptoms, which include 
tremors, rigidity and bradykinesia need to be present to make a formal diagnosis of PD 
(Duvoisin, 1984).  
 As a result of the debilitating effects of PD and the progressive nature of the 
illness, there are psychological symptoms associated with PD, which include depression, 
anxiety, numbness, restlessness, sleep difficulties, fatigue and hypotension (Fahn, 2003).  




patients (Kulisevsky, Pagonbarraga, Pascual-Sedano, Garcia-Sanchez, & Gironell, 
2008).  Depression is the most common psychiatric illness in persons with PD and 
clinically significant depressive symptoms are present in approximately 35% of persons 
with PD (Reijnders, Ehrt, Weber, Aarsland, & Leentjens, 2008).  From the research on 
the effects of PD on patients, it is evident that PD impacts every aspect of a person’s life. 
Drug Treatment  
Dopaminergic drugs are used in treating PD as they have been found to be 
effective in improving motor function, reducing morbidity and mortality of PD, and 
improving overall quality of life (Clarke, Zobkiw & Gullaksen, 1995; Rajput, 2001; 
Schapira, 2005).  Levodopa is the most common drug in this classification and 
specifically improves bradykinesia and rigidity (Schapira, 2005).  Although Levodopa 
may be effective for a number of years, its potency is modified due to disease 
progression and the loss of the dopaminergic cells needed to metabolize the drug.  As a 
result, individuals may experience motor complications or a “wearing off” syndrome 
(Schapira, 2005).  Thus, approximately 80% of patients with PD experience motor 
complications after 5-10 years of Levodopa use (Hammod, Bergman & Brown, 2007).  
Levodopa may be given in conjunction with a catechol-O-methyltransferase (COMT) 
inhibitor, which increases the absorption of Levodopa by reducing O-methylation in the 
gut (Schapira, 2005).  
Surgical Treatment of PD 
 In the past 20 years, there has been an emergence of surgical interventions as a 




used in treating PD include ablative surgery, deep brain stimulation, gene therapy, and 
neural transplantation surgery.  
Ablative Surgery 
 Ablative procedures, also known as lesioning procedures, target areas of the 
brain that produce tremors (Ahmed, Sheraz, & Ahmad, 2010).  In ablative procedures, 
surgeons create small lesions using high frequency electric currents (Ahmed et al., 
2010).  There are three types of ablative surgery: thalamotomy, pallidotomy, and 
subthalamotomy.  Thalamotomy is a surgical procedure where the ventral intermediate 
nucleus is targeted (Walter & Vitek, 2004).  Previous research has found the lesions in 
the ventral intermediate nucleus improve tremors (Ahmed et al., 2010).  Patients with 
asymmetric, severe and medically intractable tremor are recommended to have a 
thalamotomy (Ahmed et al., 2010).  There are several adverse effects as a result of 
undergoing a thalamotomy, which include paresthesias, motor weakness, dysarthria, 
disequilibrium and gait disturbance.  Bilateral thalamotomy may be conducted on 
patients with bilateral symptoms; however, there is an increased risk of speech and 
cognitive difficulties associated with bilateral thalamotomy procedures. 
 Pallidotomy is another type of ablative surgery where parts of the globus pallidus 
(GPi), are destroyed (Ahmed et al., 2010).  The GPi region of the brain controls 
movements to restore balance (Ahmed et al., 2010).  There have been two single-blind 
randomized trials completed to compare unilateral pallidotomy with drug treatments.  In 
the first study with a sample of 37 patients, Unified Parkinson’s Disease Rating Scale 
(UPDRS) “off” motor scores showed a 31% improvement from the baseline (Walter & 




conducted and researchers found 32% improvement on the “off” motor UPDRS motor 
score, which was assessed at 6 months from the baseline (Walter & Vitek, 2004;Vitek et 
al., 2003).  Overall, unilateral pallidotomy has been shown to improve drug induced 
dyskinesia, bradykinesia, rigidity and tremor (Ahmed et al., 2010).  However, the 
benefits of unilateral pallidotomy vary in long-term follow-ups (Ahmed et al., 2010).  
The third type of ablative surgery is subthalamotomy, which has received less 
attention than thalamotomy and pallidotomy.  Subthalamotomy targets the subthalamic 
nucleus in the brain.  While there have been improvements in patients with PD who have 
undergone a subthalamotomy procedure, surgeons fear performing the procedure due to 
the risk intractable hemiballism (Walter & Vitek, 2004).  However, research has shown 
subthalamotomy can be completed without concerns of hemichorea.  Studies on 
subthalamotomy showed 15-50% improvement in the “off” medicine UPDRS motor 
score at a two-year follow- up (Walter & Vitek, 2004).  In addition, bilateral 
subthalamotomy has demonstrated fewer speech and cognitive side effects compared to 
bilateral pallidotomy or thalamotomy (Walter & Vitek, 2004). 
Deep Brain Stimulation  
Deep brain stimulation (DBS) is a widely popular therapeutic treatment for PD 
and has been subject to a significant amount of research.  DBS is a surgical technique 
where continuous electrical stimulation is delivered through implanted electrodes 
connected to an internalized neuropacemaker (Benabid, 2003).  Multiple deep brain 
structures have emerged as potential therapeutic targets in treating PD (Collins, 
Lehmann, & Patil, 2009).  Research in the 1990s and early 2000s suggested the ventral 




the tremors associated with PD (Collins et al., 2009).  However, targeting the VIM in 
DBS has been shown to have little impact on the other common symptoms associated 
with PD including rigidity and bradykinesia (Collins et al., 2009).  As a result, DBS 
targeting the VIM is useful in a small percentage of patients where tremors are the 
predominant symptom.  Another area targeted in DBS is the internal globus pallidus 
(GPi), which has been shown to be effective in treating tremors while also decreasing 
symptoms of dyskinesia, rigidity and bradykinesia and improving postural stability 
(Collins et al., 2009; Obeso et al., 2001).  Additionally, stimulation of the subthalamic 
nucleus (STN) is effective for the treatment of rigidity, bradykinesia, and tremor.  One 
study examining the effectiveness of STN stimulation for PD demonstrated 
improvements of 50% in UPDRS motor scores, with improvements having been 
observed for periods of 5 years (Krack et al., 2003).  In addition, STN DBS allows 
patients with PD to have a 50% to 60% reduction in dopaminergic agent dosage, which 
may lead to an improvement in dyskinesias due to Levodopa (Hamani, Richter, Schwalb, 
& Lozano, 2005; Kleiner-Fisman, Herzog, Fisman, Tamma, Lyons et al., 2006).  
 A randomized controlled trial of DBS therapy for PD by Weaver et al. (2009) 
showed patients with PD receiving STN DBS or GPi DBS showed 4 or more hours of 
additional “on” time per day without the side effect of dyskinesia.  Additionally, the 
“off” time and “on” time with dyskinesias was reduced compared to pre-operative 
baseline (Weaver et al., 2009).  
Gene Therapy 
 Gene therapy is a promising new experimental treatment for persons with PD.  




interventions.  Gene therapy in patients with PD uses viral vectors to carry out gene 
transfer (Rodnitzky, 2012).  As a result, there is targeted protein expression in different 
areas of the brain (Rodnitzky, 2012).  There are multiple types of gene therapy: AAV-
GAD gene therapy in the subthalamic nucleus (SN), AAv2-Neurturin gene therapy 
(CERE-120), Aromatic L-amino acid decarboxylase (AADC) gene therapy, and prosavin 
(Rodnitzky, 2012).  At this point, it is still continuing to undergo human clinical trials.  
While gene therapy has shown promise, it has not yet been shown to be superior to 
surgical or pharmacologic treatments for patients with PD.  
Neural Transplantation 
 An additional experimental treatment for patients with PD is the stereotactic 
implantation of human embryonic dopamine neurons into the brain (Freed et al., 2001; 
McRae et al., 2004).  Current neural transplantation procedures include stem cell 
transplantation surgery and fetal tissue transplantation surgery.  
Neural Transplantation: Stem Cell Transplantation Surgery 
 The transplantation of stem cells into the brain has been a procedure used in 
treating neurogenerative diseases including PD.  The ability for stem cells to 
differentiate into multiple cells types or all cells of the body makes them beneficial for 
transplantation (Lindvall, Kokaia, & Martinez-Serrano, 2004).  The transplantation of 
stem cells into the brain has been shown to be possible in several clinical studies (Politis 
& Lindvall, 2012).  Given that PD is the degeneration of nigrostiatal dopaminergic 
neurons, the transplantation of human fetal mesencephalic tissue, which is rich in 
postmitotic dopaminergic neurons, has been shown to be effective in neuronal 




reinnervate the striatum for approximately 10 years (Kordower et al., 1995; Piccini et al., 
1999).  Additionally, the grafted neurons have been shown to normalize striatal 
dopamine release and reverse the progression of the cortical activation underlying 
akinesia (Lindvall et al., 2004; Piccini et al. 2000; Piccini et al., 1999).  As a result, the 
grafted dopaminergic neurons can be incorporated into the neuronal circuitries in the 
brain (Lindvall et al., 2004; Piccini et al., 2000).  
 The results of the stem cell transplantation surgery, however, are mixed (Politis 
& Lindvall, 2012).  One reason for modest effects is the limited amount of surviving 
grafted dopaminergic neurons (Lindvall et al., 2004). Research also has yet to show that 
the stem cells can “provide efficient functional reinnervation and behavioral recovery in 
animal PD models” (Lindvall & Kokaia, 2009). In addition, dyskinesias have been 
shown to develop following the transplantation, which are believed to result from 
uneven or patchy reinnervation (Lindvall et al., 2004). More research needs to be 
conducted on the efficacy of stem cell transplantation in patients with PD.  Future 
research studies will need to “require better criteria for patient selection, improved 
functional efficacy for grafts by a tailor-made transplantation procedure providing 
optimum repair of the patient’s DA system and strategies to prevent dyskinesias and 
tumor formation” (Lindvall & Kokaia, 2009).  
Neural Transplantation: Fetal Tissue Transplantation Surgery 
Fetal transplantation surgery has been investigated over the last several decades.  
Fetal transplantation surgery began in 1980’s and 1990’s when human fetal 
mesencephalic tissue was transplanted in the striatum in patients with PD (Lindvall & 




replacement works in the human brains of patients with PD (Bjorklund et al., 2003; 
Lindvall & Bjorklund, 2004).  Moreover, the early trials demonstrated human fetal 
dopaminergic neurons can survive and function in the striatrum of patients with PD for 
more than10 years (Bjorklund et al., 2003).  Following the initial trials of fetal 
transplantation in humans, the National Institutes of Health (NIH) supported additional 
efforts to investigate fetal transplantation in patients with PD (Bjorklund et al., 2003).  
As a result, two double-blind sham-surgery controlled trials were investigated in the 
1990’s (Bjorklund et al., 2003).  
 Freed et al. (2001) completed a double-blind, sham surgery controlled trial to 
examine if the transplant group improved compared to the sham group.  The 
investigators also explored whether the implanted cells survived in the patients who 
underwent the transplantation surgery and the efficacy of the transplantation on physical 
symptoms associated with PD (Freed et al., 2001). Additionally, the investigators 
determined if age was a factor in the efficacy of the transplantation procedure (Freed et 
al., 2001).  
The investigators randomly assigned 40 patients with severe PD to undergo the 
transplantation of neural cells or a sham surgery; 20 participants received the transplant 
and 20 participants received the sham surgery (Freed et al., 2001).  The participants 
ranged in age from 34 to 75-years of age and all of the participants were found to have 
had at least two of the three cardinal symptoms for more than seven years (Freed et al., 
2001).  The patients were awake during the procedure and given local anesthesia (Freed 
et al., 2001).  The transplantation procedures included a stereotactic ring being affixed to 




of the putamen with two needle tracks on each side of the brain.  During surgery, four 
burr holes were made in the patients’ forehead and cultured mesencephalic tissue from 
four embryos was transplanted into the putamen bilaterally (Freed et al., 2001).  In the 
sham surgery, the patients underwent an identical procedure, including drilling holes in 
the forehead.  However, the dura matter was not penetrated and the cultured fetal tissue 
was not placed in the brain (Freed et al., 2001).  All of the fetal transplantation 
procedures were performed at the University of Colorado Hospital (Freed et al., 2001).  
Results showed human embryonic dopamine-neuron transplants survived in all patients 
and there were some clinical benefits in younger participants (Freed et al., 2001).  More 
detailed information regarding the parent study and the fetal transplantation surgery can 
be found in the report by Freed et al. (2001).  The present study will be a longitudinal 
follow-up of individuals who participated in the study conducted by Freed et al (2001).  
An additional double-blind sham-surgery trial was undertaken by Olanow et al. 
(2003).  The study was a 24-month double-blind, placebo controlled trail of fetal nigral 
transplantation in 34 patients with advanced Parkinson’s disease (Olanow et al., 2003).  
The participating patients with PD received bilateral transplantation with one or four 
donors per side or a placebo procedure (Olanow et al., 2003).  Following the completion 
of the study, patients showed no significant overall treatment effect.  However, patients 
with milder symptoms of PD at the baseline showed significant improvements (Olanow 
et al., 2003).  
These trials exhibited variable results.  Despite several open label trials that 
showed improvements in striatal uptake of fluorine-18-labelled dopa and UPDRS motor 




One reason for the varied results in patients with PD is the differences in the survival 
and growth of the grafted dopaminergic neurons in patients.  In addition, the placebo 
effect may play a stronger role in the results than originally thought.   
Original QoL Study 
 A total of 30 participants out of the 40 from the fetal transplantation study agreed 
to participate in the QoL study conducted by McRae et al. (2004).  The QoL study 
examined the QoL and medical outcomes of the 30 patients (12 patients who received 
the transplant and 18 patients who received the sham surgery) at four, eight and twelve 
months before the double-blind was lifted.  The researchers found only one statistically 
significant difference between the two treatment groups at baseline, 4, 8, and 12 months.  
However, based on perceived treatment or the type of surgery patients’ thought they 
received, researchers found multiple differences in QoL outcomes.  For instance, at the 
12-month follow-up, participants who thought they received the transplant reported more 
positive results regarding physical functioning compared to the participants who thought 
they received the sham surgery, regardless of the actual type of surgery they received 
(McRae et al., 2004).  The results of this study illustrate the impact of the placebo effect 
on the fetal transplantation surgery trial.    
Longitudinal Follow-up at 10-12 Years After Original Study 
Cole investigated the long-term effects of the fetal transplantation surgery on 
QoL factors on the participants from the parent study (Cole, 2009).  A total of 11 
participants agreed to participate in the longitudinal follow-up study (Cole, 2009).  The 
patients’ physical, emotional and social functioning were assessed and compared to the 




study conducted by McRae et al. (2004).  All participants in the longitudinal follow-up 
study had received the transplant, either originally or after the blind was revealed and 
they were allowed to receive the transplant after first being given the sham surgery. 
The results from the study showed participants reported improvements in 
physical functioning between baseline and the two-year follow-up (Cole, 2009).  More 
specifically, the majority of the participants experienced improvements in physical 
functioning from baseline to the one-year assessment.  Following the two-year follow-
up, however, participants reported a decline in physical functioning (Cole, 2009).  
Regarding emotional functioning in the participants, the results showed improvements in 
emotional functioning between the baseline and two-year follow-up (Cole, 2009).  
During the two-year assessment and 10-12-year follow-up, however, there was a decline 
in emotional functioning, which was consistent with physical functioning (Cole, 2009).  
Social support decreased between baseline and one-year assessment but showed 
improvements at the two-year assessment (Cole, 2009).  Additionally, social support 
decreased significantly between the two-year assessment and the 10-12-year follow-up 
(Cole, 2009).  
Quality of Life  
 The exploration of QoL in patients with PD has been researched in recent 
decades to determine effective treatments in reducing both the motor and non-motor 
symptoms associated with PD.  QoL gives researchers insight into the individual 
experiences of the patients with PD and the impact of specific treatments on the patients’ 
everyday functioning.  In addition, the medical field and medical professionals have 




result, they are beginning to take a multi-dimensional approach to treating patients.  In 
other words, medical professionals are now recognizing the significant impact of non-
motor symptoms such as cognitive impairments, sleep problems, dementia and 
depression on patients with PD.  In developing treatments directed at treating both the 
motor and non-motor symptoms of PD, one of the goals is to improve quality of life.  
There are several definitions that exist regarding QoL.  Felce and Perry (1995) 
described QoL as an integration of objective and subjective factors that incorporates a 
wide range of life domains and individual values (Felce & Perry, 1995).  Quality of life 
(QoL), according to the study conducted by McRae et al., includes three dimensions: 
Physical, Emotional and Social functioning (2004).  WHO defined QoL as ‘an 
individual’s perception of his/her position in life in the context of the culture and value 
systems in which he/she lives and in relation to his/her goals, expectation, standards and 
concerns (Ferrara et al., 2010; WHOQOL Group, 1995, p. 1405).  Researchers have also 
used the concepts of health related quality of life (HRQoL) and health status (HS) to 
examine the benefits of treatments.  These concepts have been developed to encompass 
the impact of a health condition on overall functioning.  However, there are no current 
universal definitions for HRQoL and HS (Ferrara et al., 2010).  HS measures focus on 
the presence of symptoms and their impact on an individual’s ability to perform various 
daily activities such as leisure activities and housework (Ferrara et al., 2010).  In 
contrast, HRQoL measures explore a patient’s subjective experiences of symptoms and 






Quality of Life: Importance of the Patient’s View in clinical trials  
As mentioned previously, the majority of the past research conducted regarding 
treatments of PD has focused on the medical perspective and the treatment of the 
physical symptoms of the disease.  In recent years, however, research has begun to 
explore the perspectives of the patients’ with PD to gain an understanding of the impact 
of the disease on the lives of the patients.  
One study conducted by Politis et al. (2010), examined the patients’ perspectives 
regarding the symptoms associated with PD.  The researchers had the patients rank their 
three most troublesome symptoms in the last six months (Politis et al., 2010).  The 
results from the study demonstrated diversity in the experiences and perspectives of 
patients with PD.  The study found the lack of response of medication and non-motor 
symptoms were the most troublesome issues (Politis et al., 2010).  The study 
demonstrated the importance of examining the perspective of the patient with PD to treat 
both the motor and non-motor symptoms associated with PD (Politis et al., 2010).  
Moreover, the study conducted by Politis et al. emphasizes the importance of exploring 
patient’s experiences and perspectives to aid in developing patient-centered care and 
management (Politis et al., 2010).  
One method of assessing patients’ perspectives is to use QoL as a measure.  QoL 
explores the physical functioning, psychological/emotional functioning, social 
interaction with others/social support in patients with PD.  The assessment of QoL 
explores a patient’s personal experiences and beliefs regarding the progression of the 
disease and the impact on different domains of daily life.  The exploration of QoL in 




functioning and coping with the disease.  In taking a more holistic view of patients’ 
functioning, more effective treatments can be developed and designed to address both 
the motor and non-motor symptoms associated with PD.  
One study examined factors that determine QoL in patients with idiopathic PD.    
Schrag, Jahanshahi and Quinn (2000) examined the impact of PD on QoL in 124 patients 
with PD using a QoL battery including EuroQoL 5D, the Medical Outcome Study Short 
Form (SF 36) and the 39-item Parkinson’s Disease questionnaire (PDQ-39).  In addition, 
an interview and complete neurologic examination were completed.  QoL declined 
significantly with the progression of the disease and increase in disease severity (Schrag 
et al., 2000).  Physical and social functioning demonstrated the greatest decline (Schrag 
et al., 2000).  Emotional functioning showed results similar to the general population 
(Schrag et al., 2000).  
Given the progression of PD and the chronic nature of the disease, it is essential 
to explore the patient’s perspectives and QoL over a longer period of time to determine 
the effectiveness of treatments.  One study by Karlsen, Tandberg, Arsland & Larsen 
(2000) examined change in QoL in patients with PD across a four-year follow-up from a 
community-based 1993 prevalence sample (Karlsen et al., 2000).  The results of the 
study found increased distress during the four-year follow-up period, and increased 
stress correlated with increased parkinsonism as measured by UPDRS and Hoehn and 
Yahr stage.  Furthermore, pain, social isolation, and emotional reactions in addition to 
physical mobility were correlated with increased stress (Karlsen et al., 2000).  The study 




QoL of patients and how these findings may assist in targeting and treating distressing 
symptoms associated with PD that develop over time.  
Assessing QoL in the patients in the parent study illuminates the long-term 
effects of participating in a surgery trial on physical, emotional and social functioning in 
patients with PD (Cole, 2009).  More specifically, continued assessment of QoL in the 
patients in the parent study could illustrate the long-term impact of neural transplantation 
on the patients’ physical health, severity of symptoms, description of feelings, affective 
functioning, stress level, social support and interaction with others.  
Important Patient Data on Quality of Life 
 The investigation regarding how QoL has improved, worsened or stayed the 
same in individuals who underwent the neural transplantation surgery is important.  The 
present study examined the changes in QoL over time from baseline to the current 
assessment, including one and two years after the transplant surgery, 10-12 years after 
the transplant surgery in 2008 and the current assessment. The purpose of this study was 
to examine the long-term effectiveness of fetal transplantation surgery on QoL or 
patients’ physical, emotional and social functioning.  
Mixed Methods Approach 
 To examine the perspectives of the patients who participated in the parent study, 
a mixed methods approach was used.  This topic warrants a qualitative perspective given 
the importance of understanding the patient’s perspectives and personal experiences.  
Moreover, qualitative research should be conducted when a complex and detailed 




15 year follow-up using both quantitative information as well as interviews with the 
participants.  
 The concept of mixing different research methods was originated in 1959 by 
Campbell and Fiske who used mixed methods to study the validity of psychological 
traits (Creswell, 2007).  Following their research study, researchers began combining 
traditional quantitative surveys with observations and interviews (Creswell, 2007).  
Researchers also argued that there were inherent biases in using a single method 
(Creswell, 2007).  As a result, the term triangulation was created to describe the 
convergence of qualitative and quantitative methods (Creswell, 2007).  Following the 
initial exploration of using mixed methods, writers began developing specific procedures 
for conducting a mixed methods approach to research including multimethod, 
convergence, integrated and combined approaches (Creswell, 1994; 2007).   
Today, there are multiple types of mixed method approaches used in research. 
However, given the quantitative data could not be analyzed statistically, a qualitative 
approach was used as opposed to a mixed methods approach. The means scores on the 
measures for the participants will be connected with the data gathered from the 
interviews when possible.  
Summary 
Chapter Two provided a literature review on detailed information on PD, 
pharmacological treatments, surgical treatments, fetal tissue transplantation surgery, 
QoL, long-term follow-up, importance of patient views in clinical trials and mixed 




 PD impacts every aspect of a patient’s life.  There is a significant amount of 
research regarding PD and treatments for PD; however, there is a limited amount of 
research on the QoL of patients with PD from both a longitudinal and mixed methods 
approach.  In addition, there is limited information on the QoL of patients who 
underwent a fetal transplantation surgery trial.  
 The present study examined QoL in participants who received the fetal tissue 
transplantation surgery in the parent study approximately 13-15 years ago.  The study 
also examined how the physical, emotional and social functioning changed in the 
patients over time and from both a quantitative and qualitative perspective.  Chapter 






















Chapter Three describes the methodology used in the present study, including 
information on the participants, measures, and data analyses.  
Participants in Parent Parkinson’s Disease Study 
 In the parent study, participants were recruited through neurologists from the 
United States and Canada.  A total of 40 patients were accepted into the study.  Each 
participant was evaluated two times for approximately three to four days before being 
accepted into the study.  A total of 20 participants received the transplant and 20 
participants received the sham surgery. 
Participants in Original Quality of Life Study  
 A total of 30 participants from the parent study agreed to participate in the 
concurrent QoL study.  Of the 30 participants, 12 originally received the transplant and 
18 received the sham surgery (McRae et al., 2004).  
Participants in the Longitudinal Follow-up at 10-12 Years After Original Study 
 A total of 14 participants from the original QoL study were able to be contacted 
and 11 patients agreed to participate in the longitudinal follow-up study at 10-12 years 
following the original surgery. In the current investigation, patients who participated in 
the longitudinal follow-up at 10-12 years were contacted and asked to participate in the 




Participants in the current study 
 In the parent study, there were a total of 40 patients in the parent study and 30 of 
the participants agreed to participate in the original QoL study.  Of the 30 participants 
from the original study, updated contact information was identified for 7 people.  For the 
remaining participants, either contact information was unable to be found, or some 
participants had passed away.  Of the 7 participants, 5 of them agreed to participate in 
the current investigation. For the demographic variables of age, gender, ethnicity, 
duration of disease, and level of education, data were collected from the baseline 
assessment.  For the demographic variables of current living situation, marital status, 
currently paid for employment, and volunteer work, data were collected from the current 
assessment.   
Inclusion and Exclusion Criteria 
 Several inclusion criteria had to be met in order to participate in the parent study.  
The participants were required to be in an advanced stage of idiopathic PD for seven 
years or longer and needed to demonstrate some responsiveness to L-dopa.  All the 
participants had experienced a reduction in the effectiveness of the L-dopa treatment in 
addressing their symptoms.  Patients have all tried alternative forms of treatment and 
needed to be medically appropriate for the transplant surgery, including a certification by 
their attending physician.  Patients needed to demonstrate symptoms that were chronic in 
nature.  In other words, the patients needed to show symptoms, including “off” periods 
and dyskinesias or freezing, which could not be attributed to dopamine agonists.  The 
participants funded expenses not covered by the initial NIH grant for the parent studies.  




hallucinations.  In terms of neurocognitive functioning, the patients were required to 
have a normal MRI scans within the last 18 months of the start of the parent study and 
undergo a thorough neuropsychological examination (Freed et al., 2001).  The 
participants underwent a fluorodopa PET, which indicated idiopathic PD (Freed et al., 
2001).  The 40 participants all ranged in age from 34 to 75.  
 The exclusion criteria for the parent study included: severe or moderately severe 
depression, gross signs of dementia, previous brain surgery or injury, diabetes, severe 
cardiopulmonary disease, other severe medical conditions, and MRI evidence of 
cerebrovascular disease (Freed et al., 2001).  In addition, patients who did not receive a 
medical clearance from their attending physician were unable to participant in the study 
(Freed et al., 2001).  
Procedure 
All of the participants in the original QoL study and longitudinal follow-up 10-12 
years following the transplant were contacted in order to request their participation in the 
current study.  The contact information, including phone number and current address, 
was updated via the Internet.  Participants were contacted by the researcher via the 
telephone to discuss the current study and to assess their willingness to participate in the 
current study.  Participants were requested to complete questionnaires delivered in the 
mail and complete one phone interview.  The questionnaires obtained updated 
information on PD, QoL and Optimism.  The phone interview questions were developed 







 The questionnaires used in this study were a reduced version of the same 
questionnaires sent in the original study by McRae et al. (2004).  They were sent to the 
participants in the mail and included instruments to assess QoL while living with PD.  
Of note, the State-Trait Anxiety Inventory (STAI-State) was not included in the current 
questionnaire.  As a result, the composite variable of Emotional functioning could not be 
created and the three measures of depression, intrusiveness of illness and stress were 
analyzed independently. The three measures of Physical Functioning were also analyzed 
independently. Interview questionnaires were developed to assess the participants’ 
perspectives on participating in a double-blind, sham controlled surgery trial and to 
assess the impact of the transplant on their lives over time.  The questions were 
developed to assess the participants’ individual experiences and perspectives and were 
administered in one phone conversation.  The interview consisted of six questions, 
which did not overwhelm the participants and allowed adequate time to discuss each 
question thoroughly.  Participants were encouraged to expand upon their answers if they 
chose to do so.  
Measures 
The measures can be found in the Appendices B through J.  The quantitative 
measures described below were sent to the participants in the mail to be completed and 
returned to the investigator.  The qualitative interviews were conducted over the phone 
by this investigator after an introduction by her advisor, Dr. Cynthia McRae, who has 






 The participants’ level of physical functioning was assessed using the patient 
version of the Unified Parkinson’s Disease Rating Scale (UPDRS) developed by 
Montgomery, Lieberman, Singh, and Fries (1994).  The original UPDRS was developed 
for use by medical personnel to assess the physical capabilities of persons with PD.  The 
patient version of the UPDRS was designed to allow patients to subjectively rate their 
level of physical functioning and difficulties related to PD (Montgomery, Lieberman, 
Singh, & Fries, 1994).  The patient version used in this study is comprised of two scales, 
which include Activities of Daily Living (ADLs) at “Worst” (when patients are 
functioning physically at their “worst”) and Severity of Symptoms at “Worst.”  The 
Activities of Daily Living subscale is comprised of eight items, which is scored on a 
Likert scale ranging from 1) Normal, 2) Adequate, 3) Limited, 4) Need Help, to 5) 
Unable to do.  The total score ranges from 8 to 40 points where higher scores are 
indicative of a lower level of physical functioning and lower scores are indicative of 
better functioning.  The activities assessed on the scale include writing, talking, walking, 
dressing, hygiene, getting up from a chair, turning in bed, and cutting food. 
 The Severity of Symptoms Scale is comprised of five items and patients rated 
each problem at “Worst” functioning.  The rating for each item ranges from 1) Normal, 
2) Mild, 3) Moderate, 4) Severe, to 5) Very Severe.  The total score can range from 5 to 
25 with higher scores indicating poor physical functioning and lower scores indicating 
better physical functioning.  The symptoms listed on the scale include: tremor, 




 Internal consistency reliability of the subscales of the patient version of the 
UPDRS ranged from .65 to .90 (McRae et al., 2004).  The original UPDRS has 
demonstrated adequate construct validity across several widely used measures of 
physical functioning in PD (Ramaker, Marinus, Stiggelbout, & van Hilten, 2002).  
 An additional scale, the Free or Restricted Scale, was used to assess physical 
functioning of QoL.  The Free or Restricted Scale is a single, global measure that 
examines how free or restricted the person feels “in doing what you want to.”  The item 
is rated using a Likert-type scale ranging from 1 (I still do everything I want to do) to 7 
(I can no long do the things I want to do).  Higher scores indicate lower physical 
functioning and lower scores indicate better physical functioning.  
Emotional Functioning 
 Several assessments were used to determine the emotional functioning of the 
participants.  The Parkinson’s Disease (PD) Stress Scale was the measure used to assess 
stress in the participants.  The Parkinson’s Disease Stress Scale has a total of 19 items 
and patients are asked to indicate “yes” or “no” on each item.  A sample question is “I 
am sometimes embarrassed in public because of my symptoms.” The estimated 
reliability (Cronbach’s alpha) for the scale was .77 (McRae et al., 2004).  
 The participants in the study were assessed for depressive affect using the Center 
for Epidemiologic Studies Depression Scale (CESD; Radloff, 1977).  The scale has a 
total of 20- items used to assess the number and frequency of self- reported symptoms of 
depression.  Each item is rated using a 4-point scale, which ranges from 0 to 3 where 0 
indicates “less than 1 day” and 3 indicates “5 to 7 days” (Radloff, 1977). Lower scores 




symptoms (Radloff, 1977).  A sample item is “I had trouble keeping my mind on what I 
was doing.”  On the CESD, a total score can range from 0 to 60.  Scores on the CESD 
have been shown to have an internal consistency of .89 and test-retest reliability has 
been found to be satisfactory (Radloff, 1977).  Radloff reported the CESD scores have 
very good concurrent validity according to clinical and self-report criteria and substantial 
evidence of construct validity.  Craig, Richardson, Pass, and Bregman (1985) reported a 
convergent validity correlation of 0.65, which the researchers compared to Hamilton 
Rating Scale for Depression. The CESD assesses depressive symptoms and is not used 
as a tool to diagnose depression.  
 To assess the degree to which Parkinson’s disease interferes with daily living, the 
participants completed the Intrusiveness of Illness Scale.  The Intrusiveness of Illness 
Scale is important in this study since illness intrusiveness is a common underlying 
determinant of quality of life in patients suffering from a chronic illness (Devins, 2010).  
The Intrusiveness of Illness Scale is a 15-item self-report questionnaire, which measures 
the impact of an illness on daily living (Devins et al., 1984).  The self-report responses 
presented on a Likert-type scale range from 1 (very little) to 7 (a great deal).  A total 
score on the assessment can range from 15 to 105 (Devins et al., 1984).  Total scores in 
the high range indicate more intrusiveness and total scores in the low range indicate less 
intrusiveness.  One example of an individual item is “my illness interferes with my 
ability to work.”  
 The internal consistency reliability has been evaluated for the Intrusiveness of 
Illness Scale and research has shown internal consistency reliability ranging from .80 to 




been shown to be high when participants who experience changes in their illness or 
treatment have been excluded (Devins et al., 1984; McRae et al., 2004).  The assessment 
has been shown to have adequate construct validity amongst groups of participants with 
a variety of chronic illnesses.  
Social Functioning 
 The Social Provisions Scale (Cutrona & Russell, 1987) assesses social 
functioning and perceived degree to which participants’ social relationships might 
provide multiple dimensions of social support.  The Social Provisions Scale is a 24-item 
scale and contains a total of 4 items for each of the following subscales: guidance, 
reliable alliance, attachment, social integration, reassurance of worth, and opportunity to 
provide nurturance (Cutrona & Russell, 1987).  The individual items use a Likert-type 
scale ranging from 1 (strongly disagree) to 4 (strongly agree) with higher scores 
indicating more perceived social support.  The total score can range from 24 to 96.  An 
example item from the Social Provisions Scale is “I have relationships where my 
competence and skills are recognized.” 
 Cutrona, Russell and Rose (1984) evaluated internal consistency and test-retest 
reliability of the Social Provisions Scale and found internal consistency to be above .70 
across all provisions amongst a sample of 100 elderly subjects. Furthermore, Cutrona et 
al. found reliability to be .91 for the total score on the Social Provisions Scale.  
Optimism 
 To assess Optimism in the participants, the Life Orientation Test (LOT) scale 
was administered.  The LOT (Scheier & Carver, 1985) assesses dispositional optimism, 




(Scheier & Carver, 1985).  Optimism is the tendency to view the world and situations in 
a positive manner.  Several research studies have found that optimism is related to 
“adequate adjustment to difficult life circumstances in a large number of behavioral 
contexts (Carver, Scheier, Miller & Fulford, 2009; Chiesi, Galli, Primi, Borgi & 
Bonacchi, 2013).  The LOT is an eight-item measure plus four filler items that is 
“designed to assess generalized expectations for positive versus negative outcomes 
(Vassar & Bradley, 2010).  The LOT is measured on a 5-point scale ranging from 0 
(strongly disagree) to 4 (strongly agree); (Vassar & Bradley, 2010).  In order to get a 
total score, negative items are reverse coded and then added to the total score that ranges 
from 0 to 32.  Higher scores are indicative of greater optimism.  According to Scheier 
and Carver (1985), the LOT has a coefficient alpha estimate of .82 (Vassar & Bradley, 
2010). In addition, the LOT was found to have a test-retest correlation of .79 and 
adequate convergent and discriminate validity (Scheier & Carver, 1985).  
Data Analyses 
 The data analyses in the current study were completed in two stages: preliminary 
analyses and the primary analyses, which included the quantitative and qualitative data.  
The preliminary analyses included an investigation of the demographic information and 
descriptive statistics.   
 For the primary analysis of the quantitative data, it was anticipated that a 
repeated measures ANOVA would be used.  Unfortunately, all five of the participants in 
the current study did not complete assessments at all the different time points.  
Therefore, it was not possible to do the intended primary analysis.  For instance, one 




not complete the quantitative questionnaire in the current assessment.  In addition, by 24 
months after the surgery for those who initially had the sham surgery, data collection had 
essentially stopped and two participants did not complete the questionnaire.  In the 
current study, averages were calculated and plotted over the last 13-15 years to explore 
the changes over time.  In addition, each participant’s score for each measure for all the 
time points were plotted to examine the changes over time for each participant.  
 For the primary analysis of the qualitative data, there were 6 questions in the 
interview, which are presented below.  
  
Qualitative Questions  
1. How do you feel when you reflect back on your experiences in participating in the 
fetal tissue surgery trial? 
2. Have your feelings regarding your participation in the surgery trial changed over time? 
 
3. Knowing what you know now, would you volunteer to participate in this study again? 
Why or why not? 
4. What was the most positive aspect of participating in the study? 
 
5. What was the most negative aspect of participating in the study? 
 
6. What advice would you give to future participants in terms of coping with 




 The qualitative interview questions were designed to gain insight into the specific 
experiences of the participants during their participation in a unique surgery trial.  It was 
important to further explore their personal experiences to better understand why some 
participants appeared to be doing better than what would be expected given the 
progression of their PD and in contrast to other participants who had not done as well.  
In addition, it was helpful to understand what went well in the transplant surgery trial 
and what did not go well for these participants in order to provide detailed information to 
future researchers conducting a double-blind, sham controlled surgery trial with patients 
with PD.  The information gathered in the qualitative interview was developed into a 
narrative for each participant to outline their responses to each question and provide a 
detailed presentation of their overall experience in the transplant surgery trial over the 
last 13-15 years.  
In a mixed methods approach, there is an attempt to connect several forms of 
data.  However, given the quantitative data could not be statistically analyzed given the 
small sample size, a qualitative approach was used as opposed to a mixed methods 
approach. As a result, the plotted changes over time in this study will be integrated with 
the qualitative data, which explored individual perspectives of the participants.  The 
qualitative data was collected in order to provide a richer, fuller picture of the 
phenomenon than either approach could provide alone.  The plotted results of the 
quantitative data were followed by qualitative information (i.e., narratives of 
participants) that added depth and meaning to the quantitative results.  In addition, the 




responses on the qualitative interview and providing these results in both the Results and 
Discussion section.  
Summary 
Chapter Three outlined the methodology used in the current study.  More 
specifically, a description of the participants, procedures, QoL measures, and data 
analyses were provided.  Chapter Four presents the preliminary and primary results of 
























Results of the Study 
Overview 
 This chapter presents the results of both the quantitative and qualitative data 
aspects of the current study.  First, the preliminary analyses are reviewed and then the 
results of the primary analyses are reviewed in the context of the research questions.  All 
the preliminary statistical analyses were performed using the Statistical Package for the 
Social Sciences version 20.0 (SPSS 20.0).  
Participants of the current study originally represented two treatment groups; 
those who initially received the fetal tissue transplant (n=2) and those who initially 
received the sham surgery (n=3) and then later received the fetal tissue transplant in the 
parent study (Freed et al., 2001).  The primary analyses in the current study examined 
several domains of QoL and Optimism of participants at baseline, 12, and 24 months 
after the fetal tissue transplant, along with data from the10-12 year follow-up assessment 
in 2008 and current assessment.  Because of the one-year period of the double-blind, 
participants who received the sham surgery initially did not receive the fetal tissue 
surgery until more than a year after the baseline assessment.  Thus, it was decided to use 
the 12-months assessment as the new baseline for those who first received the sham 
surgery and then the transplant. Likewise, scores for the 12 and 24-month assessment 





 This section of the chapter is organized in the following manner: a) participant 
response to questionnaires and interview; b) missing data; c) participants’ demographic 
information; d) descriptive statistics related to the variables included in the study; e) 
comparison of current participants to the rest of the cohort from the parent study; f) 
reliability of variables. 
Participant Response to Questionnaires and Qualitative Interview 
Participants in the 2008 follow-up study were contacted via phone to assess their 
willingness to participate in the current study, which consisted of an interview and 
questionnaire.  There were a total of five interviews completed; however, only four 
completed questionnaires were returned.  
The questionnaires measured several domains of QoL and Optimism that had 
been assessed at previous time periods.  Aspects of Physical functioning, Emotional 
functioning, and Social functioning as well as Optimism were included in the 
questionnaire. 
 The Physical functioning dimension of QoL was assessed using the patient 
version of the Unified Parkinson’s Disease Rating Scale (UPDRS), including the 
Activity of Daily Living, Severity of Symptoms, and the Free or Restricted scales.  It 
was intended that Physical Functioning would be analyzed as a composite variable, 
which is consistent with previous analyses.  However, the scales for Physical 
Functioning were analyzed independently.  The Emotional functioning dimension of 
QoL was assessed by using the Center for Epidemiological Studies- Depression Scale 




The State-Trait Anxiety (STAI-State) was not included in the current questionnaire.  As 
a result, the scales for Emotional Functioning (Center for Epidemiological Studies- 
Depression Scale (CESD), the Intrusiveness of Illness Scale, and the Parkinson’s 
Disease Stress Scale) were analyzed independently. Social functioning (Social 
Provisions Scale) and Optimism (Life Orientation Test Scale) were also analyzed 
independently.  The four questionnaires that were received in the current study were then 
examined in contrast to data collected previously at different time periods, including 
baseline (prior to surgery), 12 and 24-months after the transplant surgery and the10-12 
year follow-up assessment conducted in 2008.  
Missing Data 
There were very little missing data in the questionnaires; however, there was one 
questionnaire that was missing the Parkinson’s Disease Stress Scale.  Most likely, the 
participant simply skipped the page accidentally.  With the exception of the one 
questionnaire missing the Parkinson’s Disease Stress Scale, there were no other missing 
data on the questionnaires.  
Demographic Information 
In the current questionnaire, there were several demographic questions 
(Appendix J) that were used to collect information on the participants’ present status.  
Information from the baseline questionnaire was also examined.  The data is presented in 
Table 1. While the majority of the participants do not currently work (four out of five), 
three of the participants who completed the questionnaire are volunteering despite being 




based on participants with PD who received fetal tissue transplantation surgery 















































Demographic Information of Participants in the Current Investigation  
 
Demographic Variables  Demographic Information  
Gender:  
            Male  




Age (from baseline assessment)  
           Mean years  
           Range  
 
46.00 ± 6.98 
40-56 
Duration of disease  
           Mean years  
           Range  
 
28.20 ± 4.49 
25-35 
Ethnicity - number  
           Native American  
           African American  
           Caucasian  
           Hispanic 
           Asian  








Duration of education completed (from baseline assessment)  
           Mean years  
           Range  
 
16.8 ± 2.75 
13 - 19  
Current living situation - number (from current assessment)  
           Living with family 
           Living with friend or roommate  
           Living alone 






Marital Status - number (from current assessment)  
           Never been married  
           Married or living with partner  
           Separated or divorced  






Currently paid for employment (from current assessment)  
           No  
           Part-time  





Volunteer work (from current assessment)  
           No  
           Yes 










In the current study, the descriptive analyses of the QoL measures were 
performed (see Table 2).  The descriptive analyses consist of the number of respondents 
at each time period along with the means and standard deviations of each measure.  For 
each QoL dimension in the current study, there are five time periods representing 
baseline (adjusted to reflect the assessment period immediately prior to surgery), 12 
months after the transplant surgery, 24-months after the transplant, 10-12 year follow-up 
















Descriptive Statistics of QoL Variables for Baseline, 12-Months, 24-Months, 10-12 year 
follow-up assessment in 2008 and Current Assessment 
QoL Variable (includes time of assessment) N Mean S.D. 
Physical Functioning     
     Activities of Daily Living at Worst Scale    
          Baseline 5 32.00 3.67 
          12 Months 5 26.20 9.20 
          24 Months 3 16.30 2.08 
          2008 4 25.25 6.29 
          Current 4 30.50 5.26 
     Severity of Symptoms at Worst Scale    
          Baseline 5 14.60 2.51 
          12 Months 5 13.00 4.36 
          24 Months 3 9.70 2.31 
          2008 4 13.00 2.00 
          Current 4 17.50 0.58 
     Free or Restricted Scale    
          Baseline 5 4.40 1.34 
          12 Months 5 3.20 1.64 
          24 Months 4 2.00 0.82 
          2008 4 2.63 0.48 
          Current 4 4.25 1.71 
Emotional Functioning     
     Center for Epidemiological Studies – 
Depression Scale        
   
          Baseline 5 7.40 4.98 
          12 Months 5 8.00 6.21 
          24 Months 4 6.25 5.91 
          2008 4 9.50 5.45 
          Current 4 16.25 7.80 
     Intrusiveness of Illness Scale    
          Baseline 5 59.40 23.80 
          12 Months 5 64.00 22.76 
          24 Months 3 50.00 17.78 
          2008 4 61.25 22.85 







Descriptive Statistics of QoL Variables for Baseline, 12-Months, 24-Months, 10-12 year 










     Parkinson’s Disease Stress Scale       
          Baseline 5 6.4 2.7 
          12 Month 5 8.4 4.22 
          24 Month  3 4 3.61 
          2008 4 5.63 3.95 
          Current 3 7.67 5.03 
Social Functioning        
     Social Provisions Scale       
          Baseline 5 83.4 8.71 
          12 Months 5 80.8 6.5 
          24 Months 4 86 12.49 
         2008 4 79.25 11.59 
         Current  4 75.5 6.81 
    Optimism       
         Baseline 5 21.8 6.61 
        12 Months 5 22.6 4.1 
        24 Months 4 23 3.92 
        2008 4 22 4.55 




Differences Between Current Participants and Rest of Cohort in Parent Study 
 McRae et al. (2014) investigated the differences between the participants in the 
current 13-15 year follow-up and the rest of the cohort that participated in the parent 
study at baseline and 12 months. The results of the study are included in Table 3. Of 
note, the baseline and 12 month assessment data was not shifted in the investigation by 
McRae et al. (2014). The results of the investigation found that four participants reported 
worse scores on the Activities of Daily Living Scale and Severity of Symptoms Scale at 
baseline compared with the other 26 participants (McRae et al., 2014).  Scores of 
measures including Optimism, Perceived Social Support, Depression, Intrusiveness of 
Illness and Stress improved over the 12 months for the four participants in the current 

















Differences between the Four Participants in the Current Study that Completed the 
Questionnaire and the Rest of the Cohort from the Original Parent Study at Baseline and 
12 months. 
 N=4 N=36 
Demographics Mean (SD) Mean (SD) 
Age 46.8 (6.3) 58.3 (9.7)* 
Gender F=4 F=15, M-20 
Duration 11.4 (4.0) 14.1 (5.7) 
   
Quality of Life N=4 N=26 
   
ADL's @ Worst 0 33.6 (2.1) 28.4 (6.8) *** 
ADL's @ Worst 12 29.8 (5.6) 26.3 (6.6) 
   
Severity @ Worst 0 15.6 (3.4) 13.5 (2.3) * 
Severity @ Worst 12 14 (3.7) 12.5 (3.2) 
   
Depression 0 38 (10.9) 31.9 (8.7) 
Depression 12 26.2 (5.3) 33.7 (8.6) * 
   
Intrusiveness 0 73.8 (21.9) 64.6 (16.3)  
Intrusiveness 12 52.4 (20.6) 67.0 (13.8)* 
   
Stress 0 7.4 (3.0) 6.1 (3.6) 
Stress 12 6.4 (4.2) 7.2 (3.4) 
   
Perceived Support 0 80.4 (10.7) 80.3 (9.0) 
Perceived Support 12 88.6 (2.1) 77.7 (10.4)**** 
   
Optimism 0 20.2 (5.9) 22.5 (5.5) 
Optimism 12 23.4 (4.6) 19.9 (3.9)* 
   
   
 * ≤  0.10 *** ≤ 0.01 




Reliability of Measures 
Because of the small sample size in the current study, estimates of reliability 
(Cronbach’s alpha) of all measures were obtained from the previous follow-up analysis 
conducted at 10-12 year follow-up assessment (see Table 4; Cole, 2009).  The Free or 



















Reliability of QoL Measures for Current Assessment 
QoL Measure at Current Assessment Cronbach’s Alpha 
  
Physical Functioning  
Activities of Daily Living at Worst Scale 
Severity of Symptoms at Worst Scale 
.88 
.68 
Emotional Functioning  
Center for Epidemiological Studies - Depression Scale  
Intrusiveness of Illness Scale 




Social Functioning  


















The previous section outlined the demographic information as well as other 
preliminary analyses.  The current section focuses on the analyses and results for the 
research questions of the study.  
Research Question #1 
What is the trajectory of change in QoL for all the participants in the current study from 
the baseline, 12 and 24 months after transplant, 10-12 follow-up assessment conducted 
in 2008 and current 13-15 year follow-up assessment?   
 After examining the data, it was evident that with such a small sample size and 
some missing data over the five time periods, using statistical analyses was not the most 
effective way to approach the data.  Instead, the means and standard deviation for each 
variable at each time point were calculated and the means were plotted in order to 
illustrate changes in the means across the five time points.  
 The profile plot presented in Figure 1, which shows the means of Activities of 
Daily Living at Worst Scale at baseline, 12, and 24 months after the transplant surgery, 
10-12 year follow-up assessment conducted in 2008 and current assessment (13-15 years 
after the real surgery).  There was an improvement in Physical functioning between 
baseline assessment and 24-month assessment and then a decline in Physical 
Functioning following the 24-month assessment. 
Figure 2 demonstrates the line of progression of Activities of Daily Living at 
Worst Scale for each participant at baseline, 12 and 24 months after the transplant 
surgery, 2008 assessment and current assessment.  Activities of Daily Living at Worst 




Physical functioning between baseline and the 24-month assessment and then a decline 






















Trajectory of Change in Activities of Daily Living at Worst Scale for Baseline to the 









































Changes in Activities of Daily Living at Worst Scale over time for Five Participants.  






















































Participant 1 Participant 2 Participant 3 




To examine changes on another aspect of Physical functioning, the means for the 
Severity of Symptoms at Worst Scale are shown in the profile plot presented in Figure 3, 
which shows the mean values of the Severity of Symptoms Scale at baseline, 12 and 24 
months after transplant, 10-12 follow-up assessment conducted in 2008 and current 13-
15 year follow-up assessment.  The means for the Severity of Symptoms Scale showed 
improvements between baseline and the 24-month assessment and then a decline 
following the 24-month assessment.  
Figure 4 demonstrates the line of progression of the Severity of Symptoms at 
Worst Scale for each participant at baseline, 12 and 24 months after transplant, 10-12 
follow-up assessment conducted in 2008 and current 13-15 year follow-up assessment. 
Three participants showed an improvement in Physical functioning between baseline and 
the 12-month assessment; however, there was one participant that showed no change in 
Physical Functioning and one participant that showed a decline in Physical Functioning 
between baseline and the 12-month assessment.  The majority of participants showed a 











Trajectory of Change in Severity of Symptoms at Worst Scale for Baseline to the 


























































































Participant 1 Participant 2 Participant 3 




To examine changes on another aspect of Physical functioning, the means for the 
Free or Restricted Scale are shown in the profile plot presented in Figure 5, which shows 
the mean values of the Free or Restricted for baseline, 12 and 24 months after transplant, 
10-12 follow-up assessment conducted in 2008 and current 13-15 year follow-up 
assessment.  The means for the Free or Restricted Scale showed an improvement in 
Physical Functioning between baseline and the 24-month assessment and then a decline 
between the 24-month assessment and current assessment.  
Figure 6 demonstrates the line of progression of the Free or Restricted Scale for 
each participant for baseline, 12 and 24 months after transplant, 10-12 follow-up 
assessment conducted in 2008 and current 13-15 year follow-up assessment.  Most of the 
participants showed an improvement or no change between the baseline assessment and 
12-month assessment; however, there was one participant that was an outlier and showed 
worse Physical functioning.  The majority of the participants showed a decline in 
physical functioning between the 24-month and current assessment.  However, there was 
one outlier (i.e., participant 2) who self-reported an improvement in physical functioning 










Trajectory of Change in Free or Restricted Scale for Baseline to the Current Assessment. 

















































































Participant 1 Participant 2 Participant 3 




 To examine the changes in Emotional functioning over the last 13-15 years, the 
means and standard deviations were computed for each time period to examine changes 
on three scales used to assess aspects of Emotional functioning includes the CESD, the 
Intrusiveness of Illness Scale, and the Parkinson’s Disease Stress Scale across the five 
time points (baseline, 12 and 24 months after the transplant surgery, 2008 and current 
assessment).  
A profile plot is presented in Figure 7, which shows the mean values for all 
participants on CESD at baseline, 12 and 24 months after transplant, 2008, and current 
assessment.  There was a mild increase in depressive symptomology from baseline to 12 
months and then decline in depressive symptomology between the 12-month assessment 
and the 24-month assessment.  From the 24-month assessment to the current assessment, 
there was an increase in depressive symptomology. 
Figure 8 demonstrates the line of progression of depression for each participant 
for the baseline, 12 and 24 months after transplant, 2008, and current 13-15 year follow-
up assessment.  Across the first three time points, there were mixed results amongst the 
participants with some participants experiencing an increase in depressive 
symptomology and some participants experiencing a decrease.  For three of the four 
participants, there was an increase in depressive symptomology between the 2008 and 








Trajectory of Change in CESD for Baseline to the Current Assessment. (lower scores 

















































































































Participant 1 Participant 2 Participant 3 




To examine changes on another aspect of Emotional functioning, the means for 
the Intrusiveness of Illness Scale are shown in the profile plot presented in Figure 9, 
which shows the mean values of the Intrusiveness of Illness at baseline, 12 and 24 
months after transplant, 10-12 follow-up assessment conducted in 2008 and current 13-
15 year follow-up assessment.  There was an increase in the Intrusiveness of Illness 
Scale between baseline and 12-month assessment as well as the 24-month assessment 
and current assessment.  There was a decline in the Intrusiveness of Illness Scale 
between the 12-month assessment and 24-month assessment.  
Figure 10 demonstrates the line of progression of the Intrusiveness of Illness 
Scale for each participant for the baseline, 12 and 24 months after transplant, 10-12 
follow-up assessment conducted in 2008 and current 13-15 year follow-up assessment.  
Intrusiveness of Illness Scale increased in the majority of the participants between 
baseline and the 24-month assessment.  The Intrusiveness of Illness Scale increased 












Trajectory of Change in the Intrusiveness of Illness Scale for Baseline to the Current 





















































































Participant1 Participant 2 Participant 3 




 To examine change on another aspect in Emotional functioning, the means were 
computed for the Parkinson’s Disease Stress Scale for each time period.  A profile plot is 
presented in Figure 11, which shows the mean values of the Parkinson’s Disease Stress 
Scale at baseline, 12 and 24 months after transplant, 10-12 follow-up assessment 
conducted in 2008 and current 13-15 year follow-up assessment.  There was an increase 
between baseline and 12-month assessment and then a decline between 12-month and 
24-month assessment.  There was an increase in stress between the 24-month assessment 
and the current assessment.  
Figure 12 demonstrates the line of progression of the Parkinson’s Disease Stress 
Scale for each participant at baseline, 12 and 24 months after transplant, 10-12 follow-up 
assessment conducted in 2008 and current 13-15 year follow-up assessment.  The 
Parkinson’s Disease Stress Scale increased for three participants and decreased for one 
participants between baseline and the 12-month assessment.  There was a decrease in the 
Parkinson’s Disease Stress Scale between the 12-month and 24-month assessment for 
the majority of the participants.  There was an increase in Parkinson’s Disease Stress 
Scale between 24-month assessment and the current assessment for two participants.  
Overall, there were mixed findings on this scale for the participants over the last 13-15 










Trajectory of Change in the Parkinson’s Disease Stress Scale for Baseline to the Current 





















































































Participant 1  Participant 2 Participant 3 




 To examine the changes in the perceived social support over time, the means 
were computed for the Social Provisions Scale for each time period.  A profile plot 
presented in Figure 13 shows the mean values of the Social Provisions Scale at baseline, 
12 and 24 months after transplant, 10-12 follow-up assessment conducted in 2008 and 
current assessment.  There was a decline in perceived social support between baseline 
and 12-month assessment, an increase between 12-month assessment and 24-month 
assessment and then decrease between 24-month assessment and the current assessment.  
 Figure 14 demonstrates the line of progression of Social Provisions Scale for 
each participant at baseline, 12 and 24 months after transplant, 10-12 follow-up 
assessment conducted in 2008 and current assessment.  There was a decrease in Social 
Functioning for three participants between baseline and the 12-month assessment.  
Social Functioning remained relatively stable between the 12-month assessment and the 
current assessment with the exception of a decline in Social functioning for two 
participants between the 10-12 year follow-up assessment and the current assessment.  











Trajectory of Change in the Social Provisions Scale for Baseline to the Current 





















































































Participant 1 Participant 2 Participant 3 




 To examine changes in the Life Orientation Test (Optimism), the means were 
computed for the Life Orientation Test for each time period.  A profile plot presented in 
Figure 15 shows the mean values of the Life Orientation Test Scale at baseline, 12 and 
24 months after transplant, 10-12 follow-up assessment conducted in 2008 and current 
13-15 year follow-up assessment.  There was an increase in Optimism between baseline 
and the 12-month assessment.  Then there was a decline between the 12-month 
assessment and 24-month assessment.  There was an increase between the 24-assessment 
and the 2008 assessment. There was a decline between the 2008 assessment and the 
current assessment. Scores range from 0-32 with higher scores indicative of more 
optimism (Scheier & Carver, 1985).  The scale has a mean score of 21 (Scheier & 
Carver, 1985).  
 Figure 16 demonstrates the line of progression of the Life Orientation Test Scale 
for each participant at baseline, 12 and 24 months after transplant, 10-12 follow-up 
assessment conducted in 2008 and current 13-15 year follow-up assessment.  There was 
no consistent pattern of change between baseline, 12-month assessment and 24-month 
assessment.  Optimism stayed relatively stable between the 24-month assessment and 
current assessment.  However, there was a decline in Optimism for one participant 










Trajectory of Change in the Life Orientation Test Scale (Optimism) for Baseline to the 








































Changes in the Life Orientation Test Scale (Optimism) over time for Five Participants.  
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Research Question #2 and #3 
What are the individual experiences of the participants who participated in the double-
blind sham controlled transplantation study and original QoL study?  Would the 
participants, who participated in original transplantation study, volunteer to participate in 
a future double-blind sham-controlled surgical trial?  
 To examine the personal experiences of the participants and to explore if they 
would participant in a future surgery trial, participants were interviewed and recorded. 
Transcripts of the recordings were made by the investigator and narratives based on the 
interviews were developed for each participant.  Individual stories for each participant 
were developed.  Each story was created by combining the individual responses to the 
qualitative questions. Pseudonyms were given to each participant for confidentiality. 
 Narrative for Susan (pseudonym) 
 When asked to reflect on her experiences in the surgery trial in the beginning of 
the discussion, Susan explained that she has had Parkinson’s disease for 40 years now 
and she was diagnosed at the age of 35.  She stated that “for [her], [the surgery] was 
extremely successful” and she feels “very positive” about the experience.  She explained 
that she “was violently dyskinetic before the surgery so afterwards [she] got great 
relief.”  She then added that she stills gets dyskinetic but “not nearly to the extent that 
[she] had been earlier.”  She then explained important activities she has been able to do 
in the years following the surgery, including developing a workshop for police officers 
following an incident where she was almost arrested due to individuals in a mall 
perceiving her as intoxicated or high on drugs.  She explained how she and her husband 




 When asked how her feelings have changed over the years, she mentioned that 
“she felt she didn’t have any other avenue “ for treatment at the time, and she was really 
“down” after she got the first surgery because she wasn’t doing well.  At that time, she 
prayed that she didn’t get the real surgery because she wasn’t doing well.  She reported 
she did receive the placebo surgery initially and she had some “placebo benefits but 
nothing [she] could dig [her] teeth in.”  She reported, “That is one thing the transplant 
did is restore some regulatory ability to my body” and she expressed that “even if you 
can stop where you are, that is a huge improvement with a chronic illness.”  She then 
explained how the surgery gave her “a second chance” in life.  She noted that she was 
able to sleep more than two hours per night, eat and gain weight, talk on the phone 
without dropping it or flinging it around the room, and walk to the end of the driveway 
and back.  She acknowledged that she was not able to do these activities previously.  She 
discussed how being able to “make [friends] a cup of tea” was a big improvement.  She 
stated she overall felt as though “life was starting over again” after the transplant 
surgery. 
 After discussing her experiences, she was asked if she would participate in a 
similar surgery trial in the future and she stated, “[She] absolutely would! I learned a 
lot.” She went on to say that “the major problems were cured and new problems arose 
that come with a chronic illness.”  She then described the surgery as “some new defense 
that you didn’t have before.”  Her husband expressed more fear regarding the process 
and indicated how it was a dangerous process because once the cells are implanted, there 
is no control over them.  He also noted he worried regarding his wife experiencing 




do a similar surgery trial in the future given that it would be intended to combat the 
illness, which is always beneficial.  
 Susan was then asked what were the positives of participating in the surgery trial 
and she stated the “outcome” and “knowing there was an opportunity to get better.”  But 
when asked the negative aspects of participating in the surgery trials, she noted the 
negative was “not knowing [if it would be beneficial].” 
 While discussing what advice would she give to future participants of a surgery 
trial, she stated to “make sure you understand the risks” associated with the study and 
then “don’t be afraid to speak up.”  She explained further that there is “nothing that is 
too little to be dealt with.”  She explained that when people enter into a surgery trial, 
they need to “trust [the researchers].”  Her husband stated that one should understand 
what the doctors want before you enter into the surgery trial.  He also explained how 
important it is to accept that things may go wrong during the surgery trial and he 
emphasized the importance of preparing the other people in your life regarding why the 
participant is participating in the study and what the outcome may be at the end.  
 At the end of the interview, Susan stated she never got to speak with other 
participants and how it would have been helpful to speak with them following the trial.  
 Narrative for Nancy (pseudonym) 
 The interview began with a discussion regarding reflecting back on her 
experiences in the surgery trial and she quickly stated that she felt the surgery was “a 
work in progress” and explained that the surgery didn’t improve her symptoms of PD 
past the first month.  Whether or not she had the real or sham surgery was discussed and 




surgery for one month including improvements in her balance and her overall tightness. 
She explained that her benefits following the real surgery were no better than with the 
sham surgery.  
 The discussion then went on to explore the negatives of the surgery trial and she 
stated she felt as though the physicians were “done with [the participants]” at the end. 
She indicated that it was a real sacrifice to participate in the study, especially with three 
young children.  As soon as her children entered the conversation, her mood shifted a bit 
and she became positive as she expressed great pride in how her children turned out.  
 She then explained she was diagnosed at age 26 and she had the surgery when 
she was 38 years old.  She indicated that she has been able to keep going as a result of 
having deep brain stimulators (DBS) inserted in 2005 or 2006.  She reported that she has 
found DBS helpful in addressing her worst symptom, which she stated is walking.  She 
stated DBS has “given [her] a whole new start.”  
 She was asked if her feelings regarding her participation in the surgery trial have 
changed over the last 13-15 years and she stated “not really.”  She explained that it was a 
trial and explained how it is important to remember that.  She acknowledged that she 
was glad she went through the trial since there was an opportunity to have input if it 
worked. She was then asked if she would do it again.  She explained that she is older 
now and doesn’t know if it would be worth it.  
 While discussing if there were any positive aspects of participating in the study, 
she noted she enjoyed “seeing other people at the level they were at.”  In other words, 
she found it helpful to see others with the disease but at different stages of the disease.  




when she was waiting to find out why it didn’t work for her and the overall results of the 
study.  
 The discussion ended up with a reflection on regarding what advice she would 
give to future participants, and she said, “Go and have it done.  If it helps, you are lucky. 
If it doesn’t help, maybe there is something else down the road.”  
 Narrative for Piper (pseudonym) 
 In looking back on her experiences in the surgery trial, Piper stated that she 
believes it is something she would do again overall and that she has no regrets.  In the 
surgery trial, she acknowledged that she had the sham surgery initially and then 
underwent the real surgery.  
 Towards the end of the surgery trial, however, she felt “abandoned” and went on 
to explain that everything was moving so quickly and then all of a sudden, there was 
nothing.  While she was grateful for the care of the nurses and physicians, at the end of 
the study, she felt as though “all of sudden [the participants] were nothing.”  
 She went on to explain how it would have been helpful to have support towards 
the end of the trial due to her experiencing ups and downs in regards to her symptoms. 
She stated it would have been helpful to know what was expected and if her symptoms 
were normal.  She pointed out that there was no one to guide her towards the end of the 
trial and give her any information.  She stated she could feel the medical staff “losing 
interest.”  She expressed sadness and stated, the participants “put time and energy into it, 
too.”  
 Regarding whether she would be willing to go through a similar surgical trial for 




future technology that would one day find a cure.  In regard to personal benefits to her 
own health, she stated “I don’t know what I would be like if I didn’t have it.”  She also 
stated she had DBS surgery approximately 8 years ago as well.  She explained that it is 
hard to tell the benefits for her since her dyskinesias are different; she experiences both 
dyskinesia and dystonia at the same and experiences more of a rolling than a jerking 
movement.   
 Over the last 13-15 years, she stated her feelings regarding participating in the 
trial have not changed and she has always been glad she participated in the trial stating, 
“I wanted to be on the cutting edge.”  She explained further that she is a “risk taker,” 
which she attributed to being a single parent and taking on new endeavors in her work 
life.  She explained that the experiences she had in the trial were unique and she would 
have never had those opportunities without the trial.  
 The discussion then turned to the waiting period between the sham surgery and 
the real surgery, which lasted approximately one year for her.  She stated it was 
“difficult” to wait that long.  She explained that every Monday she thought the phone 
call would come telling her she could undergo the transplant surgery.  However, she 
stated that instead of receiving a call from them, she had to follow-up with the doctors, 
only to find out that she need to wait several more months.  She explained that time as 
“living week to week.”  
 She went on to recall the weeks following the sham surgery and how she was 
convinced she had the real surgery initially due to “feeling better.”  She stated that when 




representing people with Parkinson’s.”  She went on to say, “I had to stay positive even 
though deep down, I didn’t believe it.”  
 During the last part of the interview, she was asked what advice she would give 
to future participants who would participate in a surgery trial.  She stated “ you can’t do 
it if you don’t believe in it.  You have to really believe in it.  You have to be positive 
about it.”  She went on to say that, “a lot of Parkinson’s has to do with your attitude” and 
stated that if you don’t make the most out of your situation, “you only hurt yourself.”  
 Narrative for Melissa (pseudonym) 
 The interview began with her feelings regarding her experiences in participating 
in the fetal tissue surgery trial.  She noted that at the beginning, she was “full of hope.” 
At that time, she was “hopeful that it would be a cure but it wasn’t.”  She went on to 
explain her symptoms three years post-surgery and stated she did pretty well.  She was 
walking and she felt “in control of [herself].”  Furthermore, she stated she was “full of 
pep” and her “tremors weren’t too bad.”  However, she acknowledged wearing off 
effects around three years.  More specifically, she noticed her left side was getting 
affected and up until that point, her left side was not affected by her PD.  She stated at 
this time, she realized that the “Parkinson’s wasn’t wearing off, [she] was wearing off.”  
 The conversation then explored her feelings in the beginning of the surgery trial. 
She stated that in the beginning, “[she] felt very special.”  She explained that she and her 
husband were recently married at the start of the study and stated they worked hard to 
join the study.  She acknowledged that during the period following surgery, there were 
several follow-up appointments where she explained how she felt “very challenged and 




found out the fetal tissue cells in one part of her brain “didn’t take.”  She also stated that 
she had some medical complications including hypertension and it was unclear at that 
time if her health issues were related to having the fetal tissue cells implanted.  She 
explained that she had to be taken off of her PD medications, which caused her 
functioning to decline and explained that as a result, the effects of the surgery didn’t last 
long.  When the effects of the surgery wore off, she explained that she experienced mild 
depression and began searching feverishly for new treatments.  At that time, she felt as 
though she was “back to square one.”  
 She was then asked how her feelings of participating in the surgery trial have 
changed over time.  She acknowledged that at the beginning, she was filled with hope 
and she felt as thought she was “dedicating [herself] to science.”  She then stated she 
does not regret being a volunteer when she reflects back on her experiences.  She also 
stated that if there were any real prospects for improvements, she would participant in a 
similar study again.  
 While inquiring regarding the most positive aspect of participating in the study 
for her, she stated it was the attention she got during the study.  When she was queried 
further, she stated she was compared to other individuals and she was invested in doing 
well.  She stated she wanted the study “to be a success.”  The discussion was then 
directed to the negative aspects of participating in the study and she stated the most 
negative aspect was having her symptoms return and then become worse.  
 Regarding advice for future participants, she stated individuals frequently come 
to her for advice regarding PD and what medications they should take since she has had 




for advice and she told her that you have to tell the doctor what you feel and you need to 
be honest with the medical providers.  She also told her friend that if you are not ready to 
take medications and if you feel you can cope without the medications, then tell the 
medical providers you are not ready.  She placed importance on being true to yourself 
and standing up for yourself. 
 She then went on to explain that she enjoys pushing herself and explained that 
she will push herself to walk outside when she is getting picked up by friends instead of 
waiting inside.  She expressed that pushing herself gives her a “sense of importance.”  
 At the end of the interview, the discussion turned to her support system during 
the surgery trial and she explained that her husband was “ a terribly good sport.”  She 
explained that he was “about helping me” and she didn’t think she “could have done it 
without his help.”  She explained that when he died, she felt “abandoned,” but she has 
good friends and she is now in a new romantic relationship. 
 The final question discussed was what she would tell someone else going 
through a similar surgery trial.  She stated she would “ask them if they have close friends 
and family.”  She then went on to say, “they would need people they care about being on 
their side” and explained that they would need to have “a conviction about helping 
others and science.” 
 Narrative for Jenny (pseudonym) 
 While reflecting back on her overall experience in the surgery trial, she stated she 
feels “very positive” regarding her experience in the transplant surgery trial.  She then 
went on to say that she had “a very good result” from the transplant surgery trial and she 




the transplant surgery.  She then went on to discuss her medical history and she noted 
she was diagnosed with PD around 1989.  She stated she is currently experiencing 
balance difficulties and she is unclear if her balance difficulties are related to her PD or 
her history of scoliosis.  
 The discussion then turned to the next question regarding how her feelings have 
changed about her participation in the surgery trial over time.  She indicated she has 
been “confident about it since the very beginning.”  She went on to explain that she 
knew she received the real transplant surgery initially because the doctors were 
“spending more detail” than they would if they weren’t putting something in her brain.  
She also noted she felt the needle pass the blood-brain barrier due to experiencing pain.  
When asked if she would participate in the surgery trial again, she quickly said yes.  
When asked to elaborate, she stated “there is nothing out there that could have given me 
as good of results or any results at all.”  She noted that she doesn’t believe the 
neurostimulators are ideal for her type of Parkinson’s.  She explained that the year 
following the transplant surgery, she was off all her medications and she was able to 
“feel like [herself].”  
 The next question explored the negative aspects of participating in the transplant 
surgery trial.  She initially stated, “I don’t know.”  She then was probed to explore the 
question further by exploring the attention she received since she was the patient that 
experienced a brain hemorrhage as a result of the transplant surgery.  She indicated the 
attention she received was “bothersome.”  The discussion then turned to when the study 
ended and how some participants felt forgotten.  She stated that was true for her as well. 




 She was then asked what advice she would give to future participants who 
participate in a fetal tissue surgery trial.  One piece of advice was that if you decide to do 
it, “act like a patient and do what you are told.”  
 Towards the end of the interview, the discussion turned to a more personal topic, 
her experiences when she was first diagnosed.  She stated her relationships have been 
“formed and deformed by Parkinson’s.”  She noted that her children had to cope with a 
“mother who moved funny.”  But she says she is grateful she is still working and she 
was able to get married again.  She also noted she was able to watch her children grow 
up. She stated regarding friendships, “it is not generally up to me, it is up to those who 
socialize with me.”  She explained that people look differently at those with chronic 
illness.  She explained that she “never felt totally comfortable with my friends and 
colleagues.  They looked at [her] as a person with Parkinson’s’ not a person.”  She then 
went on to explain how she was recently introduced by a student at a symposium and the 
student stated she was a fabulous teacher and she explained how wonderful it was for 
someone to acknowledged her as a person and teacher, rather than to see her primarily as 
someone with PD. 
Summary 
Chapter Four presented the results of the preliminary and primary analyses 
associated with the current study. In the beginning of the chapter, the results of the 
preliminary analyses were discussed, which was followed by the results of the primary 
analyses. 
 To answer the first research question, the means of all the measures were 




surgery, 10-12 follow-up assessment in 2008 and current assessment and then plotted to 
determine changes in the means over the last 13-15 years. The means for each 
participant were also computed and plotted to assess the changes from baseline through 
the current assessment. In response to the second and third research questions, the 
information gathered from the qualitative interviews was presented in narratives that 
described the participants’ individual experiences in regard to the surgical trial.  
  Chapter Five discusses the results presented in Chapter Four as well as 
connecting both the quantitative and qualitative data.  Additionally, the limitations 























 Chapter Five presents the following topics: a) summary of the current study, b) 
discussion of the overall findings from the primary analyses, c) connecting of the 
qualitative and quantitative data) d) limitations of the study, e) recommendations for 
future research, and f) conclusions. 
Summary of the Study 
 Parkinson’s disease (PD) is a chronic illness that impacts every aspect of an 
individual’s life including emotional, physical and social functioning.  There have been 
significant improvements in the treatments for PD including the introduction of surgical 
treatments over the last few decades.  In 2001, Freed et al. investigated the effects of 
fetal tissue transplantation in participants with PD by conducting a double-blind sham-
controlled surgery trial.  Results showed human embryonic dopamine-neuron transplants 
survived in all patients and there were some clinical benefits in younger participants 
(Freed et al., 2001).  While the parent study was being conducted by Freed et al. (2001), 
there was also a study that was conducted by McRae et al. (2004) that examined if QoL 
improved in participants in the transplant group compared to the sham group after the 1-
year period of the double-blind was lifted in the study conducted by Freed et al. (2001). 




surgical treatments on QoL in persons with PD.  In addition, there is little known 
regarding the long-term impact on QoL in the participants that participated in the 
double-blind, sham controlled transplant surgery trial from a qualitative perspective.  
 In the present study, the longitudinal changes in QoL in the participants after 
undergoing the fetal tissue transplantation surgery approximately 13-15 years ago were 
examined from both a quantitative and qualitative perspective.  There were a total of five 
participants who participated in the parent study (Freed et al., 2001) and original QoL 
study (McRae, 2004).  All five participants completed the interview to gather qualitative 
information regarding their personal experiences over the last 13-15 years and four 
participants completed the questionnaire that measured several dimensions of QoL as 
well as optimism.  The information gathered in the current study was plotted along with 
the data collected at baseline, 12 and 24 months after transplantation as well as the 
previous 10-12 year follow-up conducted in 2008.  The change over time in QoL was 
then charted for each participant as well as average scores at each time point on each 
measure.  Interviews were transcribed and narratives were developed to present the data 
gathered in the qualitative interview. In addition, the narratives of the participants’ were 
coded for themes in order to describe the experiences of the participants in the unique 
study. The following research questions were addressed in the current study: 
1. What is the trajectory of change in QoL for all the participants in the current 
study from the baseline, 12 and 24 months after transplant, 10-12 follow-up 
assessment conducted in 2008 and current 13-15 year follow-up assessment?  
Because of the small sample size, no statistical analyses were performed. Instead, 




plotted to examine the changes over time. In addition, individual scores on each 
of the measures were plotted over time. 
2. What are the individual experiences of the participants who participated in the 
double-blind sham controlled transplantation study and original QoL study?  
3. Would the participants, who participated in original transplantation study, 
volunteer to participate in a future double-blind sham-controlled surgical trial?  
Discussion of Overall Findings 
 In the current study, the first research question examined the trajectory of change 
in QoL (Emotional, Social and Physical functioning) and Optimism over the last 13-15 
years in the participants in the fetal tissue transplantation surgery trial conducted by 
Freed et al. (2001).  The average scores were first plotted on the three measures of 
Physical functioning: Activity of Daily Living at Worst Scale, Severity of Symptoms at 
Worst Scale and Free or Restricted Scale across the five time points including baseline, 
12 and 24 months after the transplant surgery, 10-12 year follow-up assessment in 2008 
and the current assessment.  The results of the quantitative investigation showed that the 
means for the Activity of Daily Living Scale showed improved Physical functioning 
from baseline to the 24-month assessment and then a decline in Physical functioning 
between the 24-month assessment and the current assessment.  In addition, the 
individual scores for each participant were plotted for the Activity of Daily Living Scale.  
The individual scores on the Activity of Daily Living Scale revealed that the majority of 
the participants demonstrated improvements between baseline and the 24-month 
assessment.  In addition, the majority of the participants showed worsening physical 




 The mean scores on the Severity of Symptoms Scale showed a similar pattern to 
the Activities of Daily Living Scale and there was an improvement in Physical 
functioning from the baseline assessment to the 24-month assessment followed by a 
decrease in Physical functioning between the 24-month assessment and the current 
assessment.  The individual scores revealed that there was one participant that self-
reported worsening physical functioning at the 12-month assessment followed by an 
improvement at the 10-12 year follow- up assessment in 2008.  The majority of the 
participants demonstrated improvements in functioning between baseline and the 24-
month assessment.  All of the participants self-reported worsening functioning following 
the 24-month assessment. The qualitative interviews revealed that while several 
participants have undergone additional procedures (e.g., DBS), they continue to 
experience a decline in their physical functioning. 
 The mean scores for the Free or Restricted Scale showed an improvement 
between the baseline assessment and the 24-month assessment and decline in physical 
functioning between the 24-month and the current assessment.  The individual scores on 
the Free or Restricted Scale showed that the majority of participants demonstrated an 
improvement in physical functioning between the 12-month and 24-month assessment.  
In addition, the majority of the participants showed a decline in how free or restricted 
they felt between the 24-month and current assessment.  However, there was one outlier 
(i.e., participant 2) who self-reported an improvement in physical functioning between 
the 10-12 year follow-up assessment in 2008 and the current assessment.  The qualitative 
data for participant 2 revealed that she had DBS surgery performed in 2005 or 2006, 




 The means of all the measures of Emotional Functioning (Center for 
Epidemiological Studies-Depression (CESD) Scale, Parkinson’s Disease Stress Scale 
and Intrusiveness of Illness) were then compared over the five time points as well as the 
individual scores across all five time points.  On the CESD, participants experienced a 
slight decrease in depressive symptomology between the 12 and 24-month assessment 
and then a gradual increase in depressive symptomology following the 24-month 
assessment.  On the CESD, possible scores range from 0-60 with higher scores being 
more indicative of depressive symptomology (Radloff, 1977).  The average score in the 
current assessment on the CESD Scale was 16.25 for the current assessment.  It is 
important to note that higher scores do not indicate that an individual meets the clinical 
criteria for depression.  In other words, a higher score on the CESD is indicative of more 
depressive symptoms. In reviewing the individual scores at the current assessment, two 
participants obtained scores of 9 and 10 and the other two participants received a score 
of 23.  Overall, it is surprising that the level of depressive symptoms was not higher 
across time given the progressive nature of their illness and declining physical health.  
 The average scores were analyzed for the Parkinson Disease Stress Scale across 
the five time points, which revealed a gradual increase in stress from the 24-month 
assessment to the current assessment. Notably, there was a decrease in stress between the 
12- and 24-month assessments.  It was interesting that the stress level was higher at 12-
months compared to the current assessment despite the increase following the 24-month 
assessment. The individual scores showed that an increase in stress for three participants 
at the 12-month assessment. In addition, the individual scores of the Parkinson Disease 




month assessment, while one participant showed a decrease in stress between the 10-12 
year follow-up assessment and the current assessment. The qualitative data allowed for 
insight into the high level of stress at the 12-month assessment. At the 12-month 
assessment, many participants indicated they felt abandoned by the researchers, which 
may explain the high level of stress.   
 The participants’ level of Intrusiveness of Illness was assessed and there was a 
similar pattern with the other two measures of Emotional functioning.  The level of 
Intrusiveness of Illness decreased between the 12 and 24-month assessments and then 
increased following the 24-month assessment.  The individual scores on the 
Intrusiveness of Illness scale revealed that the majority of participants reported an 
increase in Intrusiveness of Illness between the 2008 and current assessment.  Of note, 
there was a decrease in Intrusiveness of Illness for three participants between the 12-
month and 24-month assessment.  Overall, the measures of Emotional functioning 
showed a worsening in Emotional functioning (e.g., depression, stress and intrusiveness 
of illness) between 2008 and the current assessment.  However, the degree to which their 
Emotional functioning declined is less than expected given the progression of the 
participants’ PD. Several participants noted in the qualitative interviews that they 
continue to be active in their lives and contribute society in different ways such as 
volunteering.  These factors may explain why the decline is less than what would be 
expected.  
 Social functioning was assessed using the Social Provision Scale and the average 
score for each time period was plotted to determine changes over the last 13-15 years. 




perceived support. Following the 24-month assessment, there was a decline in the level 
of perceived support amongst the participants. Prior to the 24-month assessment, there 
was a decline in perceived social support at the 12-month assessment. The individual 
scores for the participants on the Social Provision Scale revealed a significant decline in 
perceived social support between the baseline and 12-month assessment. There were two 
participants who reported a decrease in perceived social support between the 10-12 year 
follow-up assessment in 2008 and the current assessment.  Two participants showed a 
slight increase in social support.  
 The trajectory of change in Life Orientation Test Scale (Optimism) was 
examined over the five time points: baseline, 12 and 24-month assessments, 10-12 year 
follow-up conducted in 2008 and the current assessment. The average scores for each 
time point were computed. There was an increase in Optimism between baseline and the 
12-month assessment.  Then there was a decline between the 12-month assessment and 
24-month assessment.  There was an increase between the 24-assessment and the 2008 
assessment. There was a decline between the 2008 assessment and the current 
assessment. A higher score is indicative of greater Optimism. Overall, the average scores 
of Optimism are higher than might be expected given the circumstances. The individual 
scores on the Life Orientation Test Scale over the five time points revealed that 
Optimism fluctuated between the baseline assessment and 24-month assessment. There 
were some participants who showed an increase in Optimism while others showed a 
decrease. Between the 24-month assessment and the current assessment, Optimism has 
remained relatively stable with the exception of one participant who exhibited a decline 




 There is very limited research on the longitudinal impact on Quality of Life in 
individuals with Parkinson’s over time. Thus, there is very little to compare the current 
quantitative findings to in the literature. There was one study conducted by Lezcano et 
al. (2004) that investigated the improvement in quality of life in individuals with 
Parkinson’s disease after undergoing bilateral deep-brain stimulation in subthalamic 
nucleus. The study found improvement in Quality of Life in 62 percent of the 
participants following two years after surgery (Lezcano et al., 2004). However, the study 
did not extend beyond two years and thus, it is difficult to compare the current findings 
to the study conducted by Lezcano et al. (2004). More research needs to be conducted on 
the long-term impact of undergoing a surgery trial on Quality of Life in individuals with 
PD. 
 In addition, a separate analysis of the data, where the current four participants 
who completed the questionnaire were compared to the rest of the cohort at baseline and 
12 months, revealed that the participants in the current assessment showed 
improvements on several measures over the 12 months (McRae et al. 2014). The rest of 
the cohort; however, showed a decline on several measures including optimism, 
perceived support, depression, intrusiveness and stress (McRae et al., 2014).  
 While the quantitative data demonstrated change in QoL over the five time 
points, the quantitative results does not provide any context or possible explanations for 
changes on the different dimensions of QoL.  Qualitative interviews were conducted in 
order to gain insight into the individual lives of the participants who participated in the 
unique double-blind, sham controlled surgery trial.  The responses of the participants 




qualitative interviews.  The qualitative data are rich with life experiences of these 
individuals and give a unique look into their individual lives during the last 13-15 years.  
The participants spoke candidly regarding the surgery trial and how their feelings have 
changed over the years as well as some of the most negative and positive aspects of 
participating in the surgery trial.  
 There were several themes that emerged during the qualitative interviews.  The 
first theme that emerged was the feeling of being “dropped” or “abandoned” following 
the surgery trial.  Several participants reported that while they received benefits from the 
surgery trial, their experiences were not validated due to the overall results of the study 
not being what was expected.  Several participants also discussed the time and energy 
they dedicated to the study and how it was disappointing to feel “abandoned” at the end. 
For instance, one participant reported that she and her husband spent hours filming her 
current functioning in order to be accepted into the study and then spent numerous hours 
flying and traveling to the participate in the surgery trial.  The feeling of being 
“abandoned” may explain the high level of stress at the 12-month assessment, which was 
essentially the end of the study for her.  
 A second theme that emerged from the data was the feeling of contributing to a 
larger cause and feeling as though as their participation in the surgery trial was one step 
closer to finding a cure for PD.  The individuals in the current study expressed a strong 
desire to participate in research and to help contribute to the body of knowledge on PD.  
It was that desire that appeared to help participants be resilient when they experienced 




would participant in the surgery trial for a second time and the majority of them felt 
positive overall regarding their experiences in the surgery trial.  
 The third theme that emerged from the data was the fact that the participants in 
the current study demonstrated a strong desire to live their lives to the fullest despite 
coping with PD for a long time.  One participant (current age is 74) stated that she 
recently began dating again and she makes herself walk to the sidewalk when her friends 
pull up in their car to pick her up.  Several other participants continue to volunteer and 
several indicated they participate in activities in order to educate others on PD.  
Connecting of the Quantitative and Qualitative Data 
 The qualitative and quantitative data allows a unique insight into the lives of the 
participants who participated in the fetal tissue surgery trial conducted by Freed et al. 
(2001) approximately 13-15 years ago.  The qualitative data can provide possible 
alternative explanations for changes in QoL beyond the scope of the fetal tissue surgery 
trial.  For instance, many of the participants have experienced loss of loved ones, 
changes in social support, changes in employment, additional procedures in order to 
alleviate symptoms of PD, and changes in how they view the trial and their current 
functioning.  
 In examining the level of depressive symptoms in the participants, it was 
interesting that several participants self-reported a minimal level of symptoms despite 
having a chronic and progressive illness and decline in physical functioning.  The 
qualitative interviews revealed that many of the participants continue to be active in 
society and contribute to the world’s knowledge regarding PD.  Despite many of the 




intrinsically motivated to be active and contribute to society.  In future studies, including 
individuals who are intrinsically motivated to contribute to society through their lives, 
their work or volunteer activities would most likely help participants be resilient in the 
face of adversity during surgery trials.  These common factors amongst the group of 
participants in the current assessment may also explain that minimal decline in other 
scales such as the Intrusiveness of Illness Scale and Optimism Scale. These findings in 
the interview are also consistent with the findings that the four participants in the current 
assessment showed improvement on several measures between baseline and 12 months 
compared to the rest of the cohort that participated in the parent study conducted by 
Freed et al. (2001). These individuals appear to be functioning better than the rest of the 
cohort on several emotional and social measures, which may serve as a protector factor 
for them over a long period of time despite having a chronic and progressive illness.  
 Another interesting finding in the data gathered was the importance of social 
support in coping with the surgery trial.  Many participants stated they relied heavily on 
their significant others or extended family members during the initial stages of the 
surgery trial.  In addition, at the current assessment, many of the participants continue to 
have strong support despite a decrease since previous time points in the quantitative 
data. Several participants have had significant others pass away since the start of the 
surgery trial.  However, many of them have gone on to find new partners or remarry.  In 
addition, it was evident in the interviews where the significant others were present that 
they also had a desire to increase knowledge regarding PD and exhibited a large 
investment in research.  In future studies, it will be pertinent to not only assess the 




willingness and ability to participate in the surgery trial.  Furthermore, social support is 
also crucial for the period of time following the surgery trial, where participants may feel 
“abandoned.”  
 Overall, the participants in the current study are remarkable human beings who 
have contributed significantly to our body of knowledge regarding PD and they are an 
inspiration in their ability to overcome adversity and live very meaningful lives 
especially after living so many years with a chronic and debilitating illness.  The data 
obtained in qualitative interviews gives the quantitative information a context and assists 
in understanding the quantitative data more holistically. 
Recommendations for Future Research 
 Recommendations for future research include establishing a comparison group. 
As future surgery trials with participants with PD take place, it will be helpful to 
compare the participants in the current assessment with participants who receive 
“standard” treatment. The comparison will allow an investigation into similarities and 
difference amongst those who received the transplant and another group of participants. 
This research will assist in furthering our knowledge regarding why participants did well 
in this surgery trial and why other participants did not do well. The findings in the 
current surgery trial suggest that the motivation to contribute to research regarding PD 
was helpful in coping with adversity and difficulties during the transplant surgery trial. It 
would be interesting to examine if this was true in similar research trials with persons 
with PD. In addition, perceived social support worsened at the 12-month assessment, 
which may be related to the feeling of being abandoned. It would be interesting to 




study. The investigation in our social support changes as the study comes to an end 
might help researchers establish more effective ways of terminating surgery trials with 
participants.  
 Another area for future research would be to assess changes in QoL from both a 
quantitative and qualitative perspective with a larger sample, which would allow for the 
quantitative data to be analyzed statistically to determine the changes in QoL are 
statistically significant.  However, this may be difficult given the limited amount of 
research in this area.  
 Future research is this area is needed to further identify factors that help 
participants do well in surgery trials in order to possibly adjust or focus the recruitment 
of participants on those with certain characteristics.  More in depth analysis of available 
data at all the time points may allow for the specific identification of factors that exist 
amongst the participants who did well in the overall study.  Another area of future 
research would be to examine all the transcripts from the different time points to further 
assess changes in QoL amongst the participants.  This would allow for further 
examination into how their perspectives have changed over the last 13-15 years. 
Furthermore, it would be interesting to compare the quantitative data using the original 










 The objective in the current study was to examine changes in QoL over the last 
13-15 years in participants who participated in the fetal tissue transplant surgery trial.  
The current study is unique in regards to the longitudinal perspective from both a 
quantitative and qualitative perspective with individuals who participated in a unique 
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Letter Sent to Participants with Questionnaire 
Dear [name], 
 Thank you so much for participating in the 13-15 year follow-up to the original 
fetal tissue implant study for the treatment of Parkinson’s Disease. It was such a pleasure 
to meet you during the phone interview. I have enjoyed learning about your experiences 
of participating in the double-blind, placebo surgery trial and the impact your 
participation has had on all the different aspects of your life as well as lives of your 
family members.  
During the phone interview, Cyndy McRae and I discussed the questionnaire that would 
be sent in the mail. I apologize for the delay in getting the questionnaire to you. I 
recently got married and moved to a different state to start my pre-doctoral internship. I 
have enclosed the questionnaire for you to complete. The questionnaire is to help us 
gather additional information about you and your participation in the fetal implant 
surgery trial. Please complete all the questions on the questionnaire. Please return the 
questionnaire in the postage paid envelope.  
Thank you so much for your time and willingness to share your experiences with Cyndy 
and I. Your contributions are incredibly beneficial to our knowledge regarding 
Parkinson’s Disease and the treatments of Parkinson’s Disease.  
Please feel to email Cyndy McRae at Cynthia.McRae@du.edu or Jessica Kuhne at 
jessicakuhne@hotmail.com if you have any questions or concerns.  
Again, thank you so much for your time. I have really enjoyed speaking with you and I 
look forward to receiving your completed questionnaires.  
 
Sincerely, 








Unified Parkinson’s Disease Rating Scale (UPDRS) – Patient Version 
How well can you perform these daily activities AT YOUR WORST?  
(check one for each row) 
   
 Normal Adequate Limited Need Help Unable To Do 
 
Walking ____ ____ ____ ____ ____ 
Dressing ____ ____ ____ ____ ____ 
Cutting food ____ ____ ____ ____ ____ 
Hygiene ____ ____ ____ ____ ____ 
Getting up from chair   ____ ____ ____ ____ ____ 
Turning in bed              ____ ____ ____ ____ ____ 
Writing   ____ ____ ____ ____ ____ 









Severity of Symptoms 
Please rate the severity of each of the following problems AT YOUR WORST. 
(check one for each row) 
 
 Normal Mild Moderate Severe Very Severe 
 
Tremor ____ ____ ____ ____ ____ 
Swallowing ____ ____ ____ ____ ____ 
Salivation ____ ____ ____ ____ ____ 
Freezing when walking     ____ ____ ____ ____ ____ 














Free or Restricted Scale 
 
Overall, how free or restricted do you feel in doing what you want to do? 
(check or circle the appropriate number) 
 
 
1         2         3         4         5         6        7   
I still do everything                                                             I can no longer do the  





Parkinson’s Disease Stress Scale 
Below you will find a list of stressful situations that may occur because of your physical 
symptoms.  Please check “Yes” or “No” to indicate whether or not an item causes you 
considerable stress, or clearly bothers you.  
 
Yes  No 
____ ____ 1. Sometimes I am embarrassed in public because of my symptoms. 
 
____ ____ 2. I attract attention in public because of my symptoms. 
 
____ ____ 3. Friends and acquaintances do not take my symptoms seriously. 
 
____ ____ 4. I cannot make new friends because of my disease. 
 
____ ____ 5. I am anxious about the uncertainty of the future of my disease. 
 
____ ____ 6. I worry a great deal about my symptoms. 
 
____ ____ 7. I worry so much about my disease that all other things become 
unimportant. 
 
____ ____ 8. My physical condition tends to determine all that I think and do. 
 
____ ____ 9. I feel like a disabled person. 
 
____ ____ 10. I feel a sense of helplessness and anger because I cannot influence 
my disease. 
 
____ ____ 11. The lives of my loved ones have changed because of my disease. 
 
____ ____ 12. Even members of my family cannot really understand the  
difficulties I face.  
 
____ ____ 13.  My partner and my family take too little notice of my disease. 
 
____ ____ 14. I am concerned that my family members restrict themselves too 
much because of my disease. 
 







Appendix E, continued 
Parkinson’s Disease Stress Scale 
Below you will find a list of stressful situations that may occur because of your physical 
symptoms.  Please check “Yes” or “No” to indicate whether or not an item causes you 
considerable stress, or clearly bothers you.  
 
Yes  No 
____ ____ 16.  Because of my disease I have had to give many personal  
responsibilities over to my partner or family members. 
 
____ ____ 17.  Because of my disease I have had to give up my job. 
 
____ ____ 18. I have the impression that my disease is not being treated properly 
by my doctor. 
 
















The Center for Epidemiologic Studies Depression Scale (CESD) 
Below is a list of ways you might have felt during the past week. Please indicate how 
often you felt or acted the way each statement suggests by using the following scale: 
 
Rarely or none of the time (Less than 1 day) 
Some or a little of the time (1-2 days) 
Occasionally or a moderate amount of time (3-4 days) 
Most all of the time (5-7 days) 
                             








1. I was bothered by things that usually 
don’t bother me. 
 
_____ _____ _____ _____ 
2. I did not feel like eating; my appetite 
was poor. 
 
_____ _____ _____ _____ 
3. I felt that I could not shake off the 
blues even with help from my family or 
friends. 
 
_____ _____ _____ _____ 
4. I felt that I was just as good as other 
people. 
 
_____ _____ _____ _____ 
5. I had trouble keeping my mind on 
what I was doing.     
 
_____ _____ _____ _____ 
6. I felt depressed. 
 
_____ _____ _____ _____ 
7. I felt that everything I did was an 
effort. 
 
_____ _____ _____ _____ 
8. I felt hopeful about the future. 
 
_____ _____ _____ _____ 
9. I thought my life had been a failure. 
 
_____ _____ _____ _____ 
10. I felt fearful. 
 
_____ _____ _____ _____ 
11. My sleep was restless. 
 





Appendix F, continued 
The Center for Epidemiologic Studies Scale (CESD) 
Below is a list of ways you might have felt during the past week. Please indicate how 
often you felt or acted the way each statement suggests by using the following scale: 
 
Rarely or none of the time (Less than 1 day) 
Some or a little of the time (1-2 days) 
Occasionally or a moderate amount of time (3-4 days) 
Most all of the time (5-7 days) 
 








12. I was happy. _____ _____ _____ _____ 
13. I talked less than usual. _____ _____ _____ _____ 
14. I felt lonely. _____ _____ _____ _____ 
15. People were unfriendly. _____ _____ _____ _____ 
16. I enjoyed life. _____ _____ _____ _____ 
17. I had crying spells. _____ _____ _____ _____ 
18. I felt sad. _____ _____ _____ _____ 
19. I felt that people disliked me. _____ _____ _____ _____ 






Intrusiveness of Illness Scale 
Using the scale below, check or circle the number that expresses how much you feel 
your Parkinson’s disease interferes with the following aspects of your life. 
 
My illness interferes with my… 
 
       Very Little               A Great Deal 
 
Body Image                               1         2         3         4        5        6         7   
 
Eating Habits    1         2         3         4        5        6         7   
 
Ability to Work   1         2         3         4        5        6         7   
 
Financial Security   1         2         3         4        5        6         7   
 
Preferred Recreation/Leisure  1         2         3         4        5        6         7   
 
Responsibility in the Family  1         2         3         4        5        6         7   
 
Family Relationships   1         2         3         4        5        6         7   
 
Marital Relationships   1         2         3         4        5        6         7   
 





Appendix G, continued 
Intrusiveness of Illness Scale 
Using the scale below, check or circle the number that expresses how much you feel 
your Parkinson’s disease interferes with the following aspects of your life. 
 
My illness interferes with my… 
Very Little              A Great 
       Deal 
Personal Relationships with Friends  1         2         3         4        5        6         7   
 
Plans for the Future    1         2         3         4        5        6         7   
 
Freedom to Choose Time Alone  1         2         3         4        5        6         7   
 
Ability to Express My Personality  1         2         3         4        5        6         7   
 
Sense of Independence   1         2         3         4        5        6         7   
 






Social Provisions Scale (SPS) 
In answering the following questions, think about your current relationships with friends, 
family members, co-workers, community members, and so on.  Please indicate to what 
extent each statement describes your current relationships with other people (check one 





Disagree Agree Strongly 
Agree 
1. There are people I can depend on to 
help me if I really need it.   
              
_____ _____ _____ _____ 
2. I feel that I do not have close personal 
relationships with other people.  
 
_____ _____ _____ _____ 
3. There is no one I can turn to for 
guidance in times of stress. 
              
_____ _____ _____ _____ 
4. There are people who depend on me 
for help. 
 
_____ _____ _____ _____ 
5. There are people who enjoy the same 
social activities I do.  
 
_____ _____ _____ _____ 
6. Other people do not view me as 
competent.  
 
_____ _____ _____ _____ 
7. I feel personally responsible for the 
well-being of another person. 
 
_____ _____ _____ _____ 
8. I feel part of a group who share my 
attitudes and beliefs. 
 
_____ _____ _____ _____ 
9. I do not thing other people respect my 
skills and abilities. 
 
_____ _____ _____ _____ 
10. If something went wrong, no one 
would come to my rescue. 
 
_____ _____ _____ _____ 
11. I have close relationships that provide 
me with a sense of emotional security and 
well-being. 




Appendix H, continued 




Disagree Agree Strongly 
Agree 
12. There is someone I could talk to about 
important decisions in my life.  
 
_____ _____ _____ _____ 
13. I have relationships where my 
competence and skill are recognized. 
 
_____ _____ _____ _____ 
14. There is no one who shares my 
interests and concerns.  
 
_____ _____ _____ _____ 
15. There is no one who really relies on 
me for their well-being.  
 
_____ _____ _____ _____ 
16. There is a trustworthy person I could 
turn to for advice if I were having 
problems. 
 
_____ _____ _____ _____ 
17. I feel a strong emotional bond with at 
least one other person. 
 
_____ _____ _____ _____ 
18. There is no one I can depend on for 
aid if I really need it. 
 
_____ _____ _____ _____ 
19. There is no one I feel comfortable 
talking about problems with. 
 
_____ _____ _____ _____ 
20. There are people who admire my 
talents and abilities.  
 
_____ _____ _____ _____ 
21. I lack a feeling of intimacy with 
another person. 
 
_____ _____ _____ _____ 
22.  There is no one who likes to do the 
things I do. 
 
_____ _____ _____ _____ 
23.  There are people I can count on in an 
emergency. 
   
_____ _____ _____ _____ 





Life Orientation Test (Optimism) 
Indicate the extent to which you agree with each of the items below. Be as accurate and 





Agree Neutral Disagree Strongly 
Disagree 
1. In uncertain times, I usually 
expect the best. 
 
_____ _____ ______ _____ _____ 
2. It’s easy for me to relax. 
 
_____ _____ ______ _____ _____ 
3. If something can go wrong 
for me, it will. 
 
_____ _____ ______ _____ _____ 
4. I always look on the bright 
side of things. 
 
_____ _____ ______ _____ _____ 
5. I’m always optimistic about 
my future. 
 
_____ _____ ______ _____ _____ 
6. I enjoy me friends a lot. 
 
_____ _____ ______ _____ _____ 
7. It’s important for me to 
keep busy. 
 
_____ _____ ______ _____ _____ 
8. I hardly ever expect things 
to go my way. 
 
_____ _____ ______ _____ _____ 
9. Things never work out the 
way I want them to. 
 
_____ _____ ______ _____ _____ 
10. I don’t get upset easily. 
 
_____ _____ ______ _____ _____ 
11. I’m a believer in the idea 
that “every cloud has a silver 
lining.” 
 
_____ _____ ______ _____ _____ 
12. I rarely count on good 
things happening to me.  
   






INFORMATION ABOUT YOU 
 
1. What is your current living situation? (check one) 
 
_____Living with a partner or family member 
_____Living with a friend or roommate 
_____Living alone 
_____Living in a residential setting 
 
2. What is your current marital status? (check one) 
 
_____Never been married 
_____Married or living with partner 
_____Separated or divorced 
_____Widowed 
 
3. If you are married to your partner, how long have you been married? _____ 
 



























Appendix J, continued 
 
Participant Demographics 
7. If not currently employed, what is the main reason? (please check one box only) 
 
_____Temporarily laid off 
_____Retired by my own choice 
_____Forced to retire by my employer 
_____Retired on physician’s advice 
_____Homemaker 
_____Poor health 
_____My job was too stressful, or physically demanding 
_____Other reason (specify): ________________________________________ 
 
8. Do you have any other chronic health problems (e.g., diabetes, heart condition, high 
blood pressure)? (check one) 
 




















1. How do you feel when you reflect back on your experiences in participating in the 
fetal tissue surgery trial? 
 
2. Have your feelings regarding your participation in the surgery trial changed over the 
last 13-15 years? 
 
3. Would you volunteer to participate in a future study? Why or why not? 
 
4. What was the most positive aspect of participating in the study? 
 
5. What was the most negative aspect of participating in the study? 
 
6. What advice would you give to future participants in terms of coping with 
participating in a surgery trial?  
 
 
 
 
 
 
 
 
 
